JP6843425B2 - Stem cell undifferentiated state maintainer and growth promoter - Google Patents

Stem cell undifferentiated state maintainer and growth promoter Download PDF

Info

Publication number
JP6843425B2
JP6843425B2 JP2016196171A JP2016196171A JP6843425B2 JP 6843425 B2 JP6843425 B2 JP 6843425B2 JP 2016196171 A JP2016196171 A JP 2016196171A JP 2016196171 A JP2016196171 A JP 2016196171A JP 6843425 B2 JP6843425 B2 JP 6843425B2
Authority
JP
Japan
Prior art keywords
stem cells
undifferentiated state
siler
extract
tribulus terrestris
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016196171A
Other languages
Japanese (ja)
Other versions
JP2018057301A (en
Inventor
祐一 長谷部
祐一 長谷部
悠一郎 大形
悠一郎 大形
克真 宮地
克真 宮地
悠 井上
悠 井上
靖司 長谷川
靖司 長谷川
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Menard Cosmetic Co Ltd
Original Assignee
Nippon Menard Cosmetic Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Menard Cosmetic Co Ltd filed Critical Nippon Menard Cosmetic Co Ltd
Priority to JP2016196171A priority Critical patent/JP6843425B2/en
Publication of JP2018057301A publication Critical patent/JP2018057301A/en
Application granted granted Critical
Publication of JP6843425B2 publication Critical patent/JP6843425B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Description

本発明は、幹細胞の未分化状態維持剤及び増殖促進剤、並びに幹細胞の未分化状態維持方法及び増殖促進方法に関する。 The present invention relates to an agent for maintaining an undifferentiated state of stem cells and an agent for promoting proliferation, and a method for maintaining an undifferentiated state of stem cells and a method for promoting proliferation.

脊椎動物(特に哺乳動物)の組織は、傷害若しくは疾患、又は加齢等に伴い細胞・臓器の損傷が起こった場合、再生系が働き、細胞・臓器の損傷を回復しようとする。この作用に、当該組織に備わる幹細胞(組織幹細胞、体性幹細胞、成体幹細胞)が大きな役割を果たしている。幹細胞は、あらゆる細胞・臓器に分化する多能性を有しており、この性質により細胞・臓器の損傷部を補うことで回復に導くと考えられている。このような幹細胞を応用した、次世代の医療である再生医療に期待が集まっている。 In vertebrate (especially mammal) tissues, when cell / organ damage occurs due to injury or disease, aging, etc., the regenerative system works to recover the cell / organ damage. Stem cells (tissue stem cells, somatic stem cells, adult stem cells) provided in the tissue play a major role in this action. Stem cells have the pluripotency to differentiate into all cells and organs, and it is thought that this property leads to recovery by compensating for damaged parts of cells and organs. Expectations are high for regenerative medicine, which is a next-generation medical treatment that applies such stem cells.

哺乳動物における幹細胞研究で最も進んでいる組織は骨髄である。骨髄には生体の造血幹細胞が存在しており、全ての血液細胞再生の源であることが明らかにされた。さらに骨髄には、造血幹細胞とは別に、臓器や組織(例えば、骨、軟骨、筋肉、脂肪等)へ分化可能な幹細胞が包含されていることが報告されている(非特許文献1参照)。 The most advanced tissue in stem cell research in mammals is the bone marrow. It has been clarified that hematopoietic stem cells of the living body are present in the bone marrow and are the source of all blood cell regeneration. Further, it has been reported that bone marrow contains stem cells capable of differentiating into organs and tissues (for example, bone, cartilage, muscle, fat, etc.) in addition to hematopoietic stem cells (see Non-Patent Document 1).

さらに、近年、骨髄以外にも、皮膚、肝臓、膵臓、脂肪等、あらゆる臓器や組織に幹細胞が存在することが明らかにされ、各臓器や組織の再生及び恒常性維持を司っていることがわかってきた(非特許文献2〜5参照)。また、各臓器や組織に存在する幹細胞は可塑性に優れており、今まで自己複製が不可能であった臓器や組織の再生にも利用できる可能性がある。 Furthermore, in recent years, it has been clarified that stem cells exist in all organs and tissues such as skin, liver, pancreas, and fat in addition to bone marrow, and it is responsible for the regeneration and maintenance of homeostasis of each organ and tissue. It has become clear (see Non-Patent Documents 2 to 5). In addition, the stem cells existing in each organ or tissue have excellent plasticity, and may be used for regeneration of organs or tissues that could not be self-replicating until now.

一方で、これらの幹細胞のうちのいくつかは、加齢とともに減少することが知られており、各組織の恒常性維持のために幹細胞の減少を防ぐ技術の研究が積極的になされている(非特許文献6)。また、近年、幹細胞の能力(多能性)を、臓器や組織の再生へ応用するため、細胞移植治療や組織工学(再生医療や再生美容)の分野において幹細胞を生体組織から分離した後に培養し増殖させる技術の開発が進められている(非特許文献7、8)。 On the other hand, some of these stem cells are known to decrease with age, and research is being actively conducted on techniques to prevent the decrease of stem cells in order to maintain homeostasis of each tissue (). Non-Patent Document 6). In recent years, in order to apply the ability (pluripotency) of stem cells to the regeneration of organs and tissues, stem cells are cultured after being separated from living tissues in the fields of cell transplantation therapy and tissue engineering (regenerative medicine and regenerative beauty). Development of a technique for breeding is underway (Non-Patent Documents 7 and 8).

特に、幹細胞を生体外で培養する場合、幹細胞の能力である多能性を維持した状態、すなわち、未分化な状態を維持させたまま増殖させることが極めて重要である。もし、この培養時に幹細胞の未分化状態が維持できず分化誘導が進んでしまった場合、最終的に調製された幹細胞の能力(多能性)は失われていることになり、目的の効果(臓器や組織の再生等)を発揮できない。 In particular, when culturing stem cells in vitro, it is extremely important to proliferate while maintaining the pluripotency of the stem cells, that is, the undifferentiated state. If the undifferentiated state of the stem cells cannot be maintained during this culture and the differentiation induction progresses, the ability (pluripotency) of the finally prepared stem cells is lost, and the desired effect (the desired effect (pluripotency) is lost. Regeneration of organs and tissues, etc.) cannot be demonstrated.

以上より、幹細胞を細胞移植治療や組織工学(再生医療や再生美容)に利用し、臓器や組織の再生を望む場合、幹細胞を、未分化状態を維持させたまま培養できなければならない。 From the above, when stem cells are used for cell transplantation therapy and tissue engineering (regenerative medicine and regenerative beauty) and the regeneration of organs and tissues is desired, the stem cells must be able to be cultured while maintaining an undifferentiated state.

現在までに、幹細胞を、未分化状態を維持させたまま増殖させる技術について、幾つか報告があるが、未だ発展途上である。例えば、胚性幹細胞(ES細胞)や造血幹細胞は、支持細胞(ストローマ細胞、又はフィーダー細胞)と共培養することで未分化を維持することができる(特許文献1及び非特許文献9〜11参照)。しかしながら、最近になってフィーダー細胞由来の内在性ウイルスによる異種動物間の感染例が報告されており(非特許文献12参照)、支持細胞を使用した幹細胞の培養は、医療用途を目的とした幹細胞の培養には適していない。 To date, there have been several reports on techniques for growing stem cells while maintaining their undifferentiated state, but they are still under development. For example, embryonic stem cells (ES cells) and hematopoietic stem cells can be maintained undifferentiated by co-culturing with supporting cells (stromal cells or feeder cells) (see Patent Document 1 and Non-Patent Documents 9 to 11). ). However, recently, cases of infection between heterologous animals by endogenous viruses derived from feeder cells have been reported (see Non-Patent Document 12), and culturing of stem cells using supporting cells is a stem cell for medical purposes. Not suitable for culturing.

その他の方法に、サイトカインを複雑に組合せることによって幹細胞の未分化状態を維持させる方法がある。例えば、マウスES細胞は、LIF(白血病抑制因子(Leukemia Inhibitory Factor))を培地に添加することによって、未分化性が維持される(特許文献2及び非特許文献13参照)。その他、初期作用性サイトカイントロンボポイエチン(TPO)、インターロイキン6(IL−6)、FLT−3リガンド、及び幹細胞因子(SCF)の存在下で、未分化性を維持させることが胚性幹細胞、体性幹細胞等で報告されている(特許文献3及び非特許文献14参照)。 Another method is to maintain the undifferentiated state of stem cells by combining cytokines in a complex manner. For example, mouse ES cells are maintained undifferentiated by adding LIF (Leukemia Inhibitory Factor) to the medium (see Patent Document 2 and Non-Patent Document 13). In addition, maintaining undifferentiated status in the presence of the early-acting cytokine thrombopoietin (TPO), interleukin 6 (IL-6), FLT-3 ligand, and stem cell factor (SCF) is an embryonic stem cell. It has been reported in somatic stem cells and the like (see Patent Document 3 and Non-Patent Document 14).

しかしながら、サイトカインは、高価であり、採取原料や保存性等の問題があり、容易な使用は難しい。加えて、LIFの効果は極めて特定の細胞系統に限定的であり、特に霊長類のES細胞や体性幹細胞においては、LIFの添加のみでは未分化状態を維持することができないことが明らかにされている(非特許文献10参照)。 However, cytokines are expensive, have problems such as raw materials for collection and storage stability, and are difficult to use easily. In addition, it was clarified that the effect of LIF is extremely limited to a specific cell lineage, and that the undifferentiated state cannot be maintained by adding LIF alone, especially in primatological ES cells and somatic stem cells. (See Non-Patent Document 10).

このように、現在、報告されている幹細胞の未分化状態の維持方法はいずれも、煩雑な操作を必要とし、また未分化状態の維持効果が低い。従って、幹細胞を再生医療に利用するために、幹細胞を、未分化状態を維持したまま増殖させる技術が求められていた。つまり、安全且つ簡便で効率的に、幹細胞を、未分化状態を維持させたまま増殖させることができる技術が求められていた。 As described above, all of the currently reported methods for maintaining the undifferentiated state of stem cells require complicated operations, and the effect of maintaining the undifferentiated state is low. Therefore, in order to utilize stem cells for regenerative medicine, there has been a demand for a technique for proliferating stem cells while maintaining an undifferentiated state. That is, there has been a demand for a technique capable of proliferating stem cells safely, easily and efficiently while maintaining an undifferentiated state.

ハマビシ(学名:Tribulus terrestris Linne)は、ハマビシ科ハマビシ属の多年草であり、生薬の疾梨子(シツリシ)は、その未熟果を乾燥させたもので、フラボノイドのケンフェロールなどを含み、利尿、消炎、解毒、降圧、鎮静等の作用を有する漢方薬に用いられている。ハマビシ(疾梨子)はまた、単独で又は他の植物抽出物と組み合わせて、エラスターゼ活性阻害作用(特許文献4)、歯周組織再生促進作用(特許文献5)などがあることが報告されている。ボウフウ(学名:Saposhnikovia divaricata Schischkin)は、セリ科ボウフウ属の多年草であり、生薬の防風(ボウフウ)は、その根又は根茎を乾燥させたもので、クマリン誘導体及びクロモン誘導体等を含み、発汗、解熱、消炎、鎮痛等の作用を有する漢方薬に用いられている。ボウフウ(防風)はまた、単独で又は他の植物抽出物と組み合わせて、抗肥満作用(特許文献6)、保湿作用(特許文献7)などがあることが報告されている。アカヤジオウ(学名:Rehmannia glutinosa Liboschitz var. purpurea)は、ゴマノハグサ科ジオウ属の多年草であり、生薬の地黄(ジオウ)は、その根を乾燥又は蒸して乾燥させたもので、イリドイド配糖体等を含み、補血、強壮、止血などの作用を有する漢方薬に用いられている。アカヤジオウ(地黄)はまた、単独で又は他の植物抽出物と組み合わせて、IV型コラーゲン産生促進作用(特許文献8)、毛成長サイトカイン産生促進による育毛効果(特許文献9)などがあることが報告されている。しかしながら、ハマビシ、ボウフウ、アカヤジオウの幹細胞の増殖促進効果や未分化状態維持効果については、これまで何ら知られていない。 Tribulus terrestris Linne (scientific name: Tribulus terrestris Linne) is a perennial plant belonging to the genus Puncture vine of the family Caltropaceae. It is used in Chinese herbal medicines that have detoxification, antihypertensive, and sedative effects. Tribulus terrestris (Tribulus terrestris) has also been reported to have an elastase activity inhibitory action (Patent Document 4), a periodontal tissue regeneration promoting action (Patent Document 5), and the like, alone or in combination with other plant extracts. .. Siler (scientific name: Saposhnikovia divaricata Schischkin) is a perennial plant belonging to the genus Siler of the Umbelliferae family. It is used in Chinese herbal medicines that have anti-inflammatory and analgesic effects. It has been reported that Siler (windproof) has an anti-obesity effect (Patent Document 6), a moisturizing effect (Patent Document 7), and the like, alone or in combination with other plant extracts. Rehmannia glutinosa Liboschitz var. Purpurea (scientific name: Rehmannia glutinosa Liboschitz var. Purpurea) is a perennial plant belonging to the genus Rehmannia glutinosa. It is used in Chinese herbal medicines that have actions such as blood supplementation, tonicity, and hemostasis. It has also been reported that Rehmannia glutinosa (Rehmannia glutinosa) has a type IV collagen production promoting action (Patent Document 8), a hair growth effect by promoting hair growth cytokine production (Patent Document 9), etc., alone or in combination with other plant extracts. Has been done. However, nothing has been known so far about the effect of promoting the proliferation of stem cells of Tribulus terrestris, Siler, and Rehmannia glutinosa and the effect of maintaining an undifferentiated state.

特開2004−24089号公報Japanese Unexamined Patent Publication No. 2004-24089 特表2002−525042号公報Special Table 2002-525402A 特許第3573354号公報Japanese Patent No. 35733554 特開2002−363088号公報Japanese Unexamined Patent Publication No. 2002-363088 国際公開第2008/099853号International Publication No. 2008/099853 特開平11−130686号公報Japanese Unexamined Patent Publication No. 11-13586 特開2006−342067号公報Japanese Unexamined Patent Publication No. 2006-342067 特開2009−298723号公報Japanese Unexamined Patent Publication No. 2009-298723 特開2013−213039号公報Japanese Unexamined Patent Publication No. 2013-21039

Pittenger M.F.ら, Science,1999年, Vol. 284, pp. 143−147Pittenger M. et al. F. Et al., Science, 1999, Vol. 284, pp. 143-147 Goodell M.A.ら, Nat. Med., 1997年, Vol. 3, pp. 1337−1345Goodell M. A. Et al., Nat. Med. , 1997, Vol. 3, pp. 1337-1345 Zulewski H.ら, Diabetes, 2001年, Vol. 50, pp. 521−533Zulewski H. Et al., Diabetes, 2001, Vol. 50, pp. 521-533 Suzuki A.ら, Hepatology, 2000年, Vol. 32, pp. 1230−1239Suzuki A. Et al., Hepatology, 2000, Vol. 32, pp. 1230-1239 Zuk P.A.ら, Tissue Engineering, 2001年, Vol. 7, pp. 211−228Zuk P. A. Et al., Tissue Engineering, 2001, Vol. 7, pp. 211-228 長谷川靖司,Aesthetic Dermatology, 2013年, Vol. 23, pp. 1−11Yasushi Hasegawa, Aesthetic Dermatology, 2013, Vol. 23, pp. 1-11 馬渕 洋 他, 日本再生医療学会誌, 2007年, Vol. 6, pp. 263−268Hiroshi Mabuchi et al., Journal of the Japanese Society of Regenerative Medicine, 2007, Vol. 6, pp. 263-268 北川 全 他, 日本再生医療学会誌, 2008年, Vol. 7, pp. 14−18Zen Kitagawa et al., Journal of the Japanese Society of Regenerative Medicine, 2008, Vol. 7, pp. 14-18 Thomson J.A.ら, Proc. Natl. Acad. Sci. USA, 1995年, Vol. 92, pp. 7844−7848Thomason J. A. Et al., Proc. Natl. Acad. Sci. USA, 1995, Vol. 92, pp. 7844-7884 Thomson J.A.ら, Science, 1998年, Vol. 282, pp. 1145−1147Thomason J. A. Et al., Science, 1998, Vol. 282, pp. 1145-1147 Reubinoff B.E.ら, Nature Biotech., 2000年, Vol. 18, pp. 399−404Reubinoff B. E. Et al., Nature Biotechnology. , 2000, Vol. 18, pp. 399-404 van der Laan L.J.ら, Nature, 2000年, Vol. 407, pp. 90−94van der Laan L. J. Et al., Nature, 2000, Vol. 407, pp. 90-94 Smith A.G.ら, Dev. Biol., 1987年, Vol. 121, pp. 1−9Smith A. G. Et al., Dev. Biol. , 1987, Vol. 121, pp. 1-9 Madlambayan G.J.ら, J. Hematother. Stem Cell Res., 2001年, Vol. 10, pp. 481−492Madlambayan G.M. J. Et al., J. Hematother. Stem Cell Res. , 2001, Vol. 10, pp. 481-492

本発明は、上述した実情に鑑み、幹細胞を、未分化状態を維持させたまま、効率良く増殖させることができる新たな物質を見出し、幹細胞の未分化状態維持剤又は増殖促進剤として提供することを課題とする。 In view of the above-mentioned circumstances, the present invention finds a new substance capable of efficiently proliferating stem cells while maintaining the undifferentiated state, and provides the stem cells as an undifferentiated state maintaining agent or a growth promoting agent. Is the subject.

本発明者らは、上記課題を解決するため鋭意研究を行った結果、ハマビシ、ボウフウ、及びアカヤジオウから選択される1種又は2種以上の植物の抽出物が、これまで知られていなかった幹細胞に対する優れた未分化状態維持効果及び増殖促進効果を有することを見出し、本発明を完成するに至った。 As a result of diligent research to solve the above problems, the present inventors have found that one or more plant extracts selected from Tribulus terrestris, Siler, and Rehmannia glutinosa are previously unknown stem cells. The present invention has been completed by finding that it has an excellent effect of maintaining an undifferentiated state and an effect of promoting proliferation.

すなわち、本発明は、以下を包含する。
(1)ハマビシ、ボウフウ、及びアカヤジオウから選択される1種又は2種以上の植物の抽出物を有効成分として含有する幹細胞の未分化状態維持剤。
(2)ハマビシ、ボウフウ、及びアカヤジオウから選択される1種又は2種以上の植物の抽出物を有効成分として含有する幹細胞の増殖促進剤。
(3)幹細胞を、ハマビシ、ボウフウ、及びアカヤジオウから選択される1種又は2種以上の植物の抽出物を含有する培地で培養する工程を含む、幹細胞の製造方法。
(4)幹細胞を、ハマビシ、ボウフウ、及びアカヤジオウから選択される1種又は2種以上の植物の抽出物を含有する培地で培養する工程を含む、幹細胞の未分化状態維持方法。
(5)幹細胞を、ハマビシ、ボウフウ、及びアカヤジオウから選択される1種又は2種以上の植物の抽出物を含有する培地で培養する工程を含む、幹細胞の増殖促進方法。
That is, the present invention includes the following.
(1) An agent for maintaining an undifferentiated state of stem cells, which contains an extract of one or more kinds of plants selected from Tribulus terrestris, Siler, and Rehmannia glutinosa as an active ingredient.
(2) A stem cell growth-promoting agent containing an extract of one or more plants selected from Tribulus terrestris, Siler, and Rehmannia glutinosa as an active ingredient.
(3) A method for producing stem cells, which comprises a step of culturing stem cells in a medium containing an extract of one or more kinds of plants selected from Tribulus terrestris, Siler, and Akayaziou.
(4) A method for maintaining an undifferentiated state of stem cells, which comprises a step of culturing the stem cells in a medium containing an extract of one or more kinds of plants selected from Tribulus terrestris, Siler, and Akayajiou.
(5) A method for promoting proliferation of stem cells, which comprises a step of culturing stem cells in a medium containing an extract of one or more kinds of plants selected from Tribulus terrestris, Siler, and Rehmannia glutinosa.

本発明によれば、幹細胞を、未分化状態を維持したまま、効率的に増殖させることができる。従って、本発明は、再生医療や再生美容の分野において大きく貢献できるものである。 According to the present invention, stem cells can be efficiently proliferated while maintaining an undifferentiated state. Therefore, the present invention can make a great contribution in the fields of regenerative medicine and regenerative cosmetology.

以下、本発明を詳細に説明する。
本発明に係る幹細胞の未分化状態維持剤又は増殖促進剤は、ハマビシ、ボウフウ、及びアカヤジオウから選択される1種又は2種以上の植物の抽出物を有効成分として含有する。
Hereinafter, the present invention will be described in detail.
The undifferentiated state-maintaining agent or growth-promoting agent for stem cells according to the present invention contains an extract of one or more plants selected from Tribulus terrestris, Siler, and Rehmannia glutinosa as an active ingredient.

本発明において用いるハマビシ(学名:Tribulus terrestris Linne)は、ハマビシ科(Zygophyllaceae)ハマビシ属(Tribulus)に属する多年草で、生薬の「シツリシ」(和名:疾梨子、学名:Tribuli Fructus)の基原植物である。本発明に用いるハマビシは、その同属又は近縁植物でもよく、また産地も問わない。本発明において、ハマビシの抽出物は、その葉、茎、果実、果皮、花、花芽、種子、全草、根、根茎等の植物体の一部又は植物体全体、あるいはそれらの混合物の抽出物をいうが、本発明において抽出原料として使用する部位は、生薬の「シツリシ(疾梨子)」として用いられる果実、特に未熟果が好ましい。 Tribulus terrestris Linne (scientific name: Tribulus terrestris Linne) used in the present invention is a perennial plant belonging to the genus Tribulus of the family Caltropaceae (Zygophyllaceae), and is the base plant of the crude drug "Siturishi" (Japanese name: Shuriko, scientific name: Tribuli Fructus). Is. The Tribulus terrestris used in the present invention may be a plant of the same genus or a closely related plant, and may be produced in any place. In the present invention, the extract of Hamabishi is an extract of a part of a plant such as leaves, stems, fruits, pericarp, flowers, flower buds, seeds, whole plants, roots, rhizomes, the whole plant, or a mixture thereof. However, in the present invention, the site used as an extraction raw material is preferably a fruit used as a crude drug "Rhizome", particularly an immature fruit.

本発明において用いるボウフウ(学名:Saposhnikovia divaricata Schischkin)は、セリ科(Umbelliferae)ボウフウ属(Saposhnikovia)に属する多年草で、生薬の「ボウフウ」(和名:防風、学名:Saposhnikoviae Radix)の基原植物である。本発明に用いるボウフウは、その同属又は近縁植物でもよく、また産地も問わない。本発明において、ボウフウの抽出物は、その葉、茎、果実、果皮、花、花芽、種子、全草、根、根茎等の植物体の一部又は植物体全体、あるいはそれらの混合物の抽出物をいうが、本発明において抽出原料として使用する部位は、生薬の「ボウフウ(防風)」として用いられる根が好ましい。 Siler (scientific name: Saposhnikovia divaricata Schischkin) used in the present invention is a perennial plant belonging to the genus Saposhnikovia of the Umbelliferae family, and is the base plant of the crude drug "Siler" (Japanese name: windbreak, scientific name: Saposhnikoviae Radix). is there. The Siler used in the present invention may be a plant of the same genus or a closely related plant, and may be produced in any place. In the present invention, the extract of Siler is an extract of a part of a plant such as leaves, stems, fruits, peels, flowers, flower buds, seeds, whole plants, roots, rhizomes, the whole plant, or a mixture thereof. However, in the present invention, the part used as the extraction raw material is preferably the root used as the crude drug "Siler (windproof)".

本発明において用いるアカヤジオウ(学名:Rehmannia glutinosa Liboschitz var. purpurea)は、ゴマノハグサ科(Scrophulariaceae)ジオウ属(Rehmannia)に属する多年草で、生薬の「ジオウ」(和名:地黄、学名:Rehmanniae Radix)の基原植物である。本発明に用いるアカヤジオウは、その同属又は近縁植物(例えば、カイケイジオウ(学名:Rehmannia glutinosa Liboschitz var. hueichingensis)等)でもよく、また産地も問わない。本発明において、アカヤジオウの抽出物は、その葉、茎、果実、果皮、花、花芽、種子、全草、根、根茎等の植物体の一部又は植物体全体、あるいはそれらの混合物の抽出物をいうが、本発明において抽出原料として使用する部位は、生薬の「ジオウ(地黄)」として用いられる根が好ましい。 Rehmannia glutinosa Liboschitz var. Purpurea (scientific name: Rehmannia glutinosa Liboschitz var. Purpurea) is a perennial plant belonging to the genus Rehmannia of the figwort family (Scrophulariaceae) It is a protozoan. The Rehmannia glutinosa used in the present invention may be a plant of the same genus or related plants (for example, Rehmannia glutinosa Liboschitz var. Hueichingensis), and may be produced in any place. In the present invention, the extract of Rehmannia glutinosa is an extract of a part of a plant such as leaves, stems, fruits, peels, flowers, flower buds, seeds, whole plants, roots, rhizomes, the whole plant, or a mixture thereof. However, in the present invention, the part used as the extraction raw material is preferably the root used as the crude drug "Gio".

ハマビシ、ボウフウ、及びアカヤジオウの抽出には、上記の抽出材料をそのまま使用してもよく、乾燥、粉砕、細切等の処理を行ってもよい。 For the extraction of Tribulus terrestris, Siler, and Rehmannia glutinosa, the above-mentioned extraction materials may be used as they are, or may be subjected to treatments such as drying, crushing, and shredding.

ハマビシ、ボウフウ、及びアカヤジオウからの抽出物の抽出方法は特に限定されず、例えば、加熱抽出方法であっても良いし、常温や冷温抽出方法であっても良い。抽出に使用する溶媒としては、例えば、水、低級アルコール類(メタノール、エタノール、1−プロパノール、2−プロパノール、1−ブタノール、2−ブタノール等)、液状多価アルコール類(1,3−ブチレングリコール、プロピレングリコール、グリセリン等)、ケトン類(アセトン、メチルエチルケトン等)、アセトニトリル、エステル類(酢酸エチル、酢酸ブチル等)、炭化水素類(ヘキサン、ヘプタン、流動パラフィン等)、エーテル類(エチルエーテル、テトラヒドロフラン、プロピルエーテル等)等が挙げられる。好ましくは、水、低級アルコール及び液状多価アルコールが良く、特に好ましくは、水、エタノールが良い。これらの溶媒は1種でも2種以上を混合して用いても良く、例えば30〜70v/v%のエタノール水溶液を使用することもできる。また、上記抽出溶媒に酸やアルカリを添加して、pH調整した溶媒を使用することもできる。 The extraction method of the extracts from Tribulus terrestris, Siler, and Rehmannia glutinosa is not particularly limited, and may be, for example, a heat extraction method or a normal temperature or cold temperature extraction method. Examples of the solvent used for extraction include water, lower alcohols (methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, etc.) and liquid polyhydric alcohols (1,3-butylene glycol). , Propylene glycol, glycerin, etc.), ketones (acetone, methyl ethyl ketone, etc.), acetonitrile, esters (ethyl acetate, butyl acetate, etc.), hydrocarbons (hexane, heptane, liquid paraffin, etc.), ethers (ethyl ether, tetrahydrofuran, etc.) , Propyl ether, etc.) and the like. Water, lower alcohols and liquid polyhydric alcohols are preferable, and water and ethanol are particularly preferable. These solvents may be used alone or in admixture of two or more, and for example, an aqueous ethanol solution of 30 to 70 v / v% can be used. It is also possible to use a solvent whose pH is adjusted by adding an acid or an alkali to the above extraction solvent.

上述の溶媒を用いて、ハマビシ、ボウフウ、及びアカヤジオウを溶媒抽出に供する。溶媒に対するハマビシ、ボウフウ、及びアカヤジオウの割合は、例えば1〜50%(w/w)、好ましくは5〜25%(w/w)が挙げられる。例えば、ハマビシの未熟果、ボウフウの根、アカヤジオウの根の乾燥物に水を加え、95〜100℃における熱水抽出を行うことで、ハマビシ、ボウフウ、及びアカヤジオウの抽出物を得ることができる。あるいは、ハマビシの未熟果、ボウフウの根、アカヤジオウの根の乾燥物に低級アルコール(例えば、エタノール等)又は液状多価アルコール(例えば、プロピレングリコール、1,3−ブチレングリコール等)を添加し、常温(例えば5〜35℃)で抽出を行うことで、ハマビシ、ボウフウ、及びアカヤジオウの抽出物を得ることができる。 Tribulus terrestris, Siler, and Rehmannia glutinosa are subjected to solvent extraction using the above-mentioned solvents. The ratio of Tribulus terrestris, Siler, and Rehmannia glutinosa to the solvent is, for example, 1 to 50% (w / w), preferably 5 to 25% (w / w). For example, extracts of Tribulus terrestris, Siler, and Rehmannia glutinosa can be obtained by adding water to the unripe fruit of Tribulus terrestris, the root of Siler, and the dried product of the root of Rehmannia glutinosa and performing hot water extraction at 95 to 100 ° C. Alternatively, lower alcohol (eg, ethanol, etc.) or liquid polyhydric alcohol (eg, propylene glycol, 1,3-butylene glycol, etc.) is added to the dried fruits of Tribulus terrestris, Siler root, and Akayaziou root, and at room temperature. Extracts of Tribulus terrestris, Siler, and Akayaziou can be obtained by performing extraction at (for example, 5 to 35 ° C.).

溶媒抽出後、得られた溶媒相自体をハマビシ、ボウフウ、及びアカヤジオウの抽出物とすることができる。あるいは、必要に応じて、得られた溶媒相を、濃縮(減圧濃縮、膜濃縮などによる濃縮)、希釈、濾過、乾燥等の処理及び活性炭等による脱色、脱臭処理等に供して、得られた生成物をハマビシ、ボウフウ、及びアカヤジオウの抽出物とすることができる。特に、抽出した溶液を濃縮乾固、噴霧乾燥、凍結乾燥等の処理に供し、得られた乾燥物をハマビシ、ボウフウ、及びアカヤジオウの抽出物として用いることが好ましい。 After solvent extraction, the obtained solvent phase itself can be used as an extract of Tribulus terrestris, Siler, and Rehmannia glutinosa. Alternatively, if necessary, the obtained solvent phase was subjected to treatments such as concentration (concentration by vacuum concentration, membrane concentration, etc.), dilution, filtration, drying, etc., and decolorization, deodorization treatment, etc. with activated carbon, etc. The product can be an extract of Tribulus terrestris, Siler, and Akayajiou. In particular, it is preferable that the extracted solution is subjected to treatments such as concentrated drying, spray drying, freeze-drying, etc., and the obtained dried product is used as an extract of Tribulus terrestris, Siler, and Rehmannia glutinosa.

このようにして得られたハマビシ、ボウフウ、及びアカヤジオウの抽出物は、生体レベルで又は培養レベルで未分化状態を維持させつつ幹細胞を効率的に増殖させる作用を有するので、幹細胞の未分化状態維持剤又は増殖促進剤として使用できる。ハマビシ、ボウフウ、及びアカヤジオウの抽出物は1種を用いてもよいが、2種又は3種を併用すると幹細胞の未分化状態維持効果及び増殖促進効果が増強するので好ましい。ハマビシ、ボウフウ、及びアカヤジオウの抽出物の2種又は3種を併用する場合、その組み合わせや混合比率は限定されない。さらに、本発明に係る幹細胞の未分化状態維持剤又は増殖促進剤は、幹細胞を、未分化状態を維持しつつ効率的に増殖させるための幹細胞培養用培地添加剤、研究用試薬としても使用することができる。 The extracts of Tribulus terrestris, Siler, and Rehmannia glutinosa thus obtained have the effect of efficiently proliferating stem cells while maintaining the undifferentiated state at the biological level or the culture level, and thus maintain the undifferentiated state of the stem cells. It can be used as an agent or a growth promoter. One type of extract of Tribulus terrestris, Siler, and Rehmannia glutinosa may be used, but it is preferable to use two or three types in combination because the effect of maintaining the undifferentiated state of stem cells and the effect of promoting proliferation are enhanced. When two or three kinds of extracts of Tribulus terrestris, Siler, and Rehmannia glutinosa are used in combination, the combination and mixing ratio are not limited. Furthermore, the undifferentiated state-maintaining agent or growth-promoting agent for stem cells according to the present invention is also used as a medium additive for stem cell culture and a research reagent for efficiently proliferating stem cells while maintaining the undifferentiated state. be able to.

本発明に係る幹細胞の未分化状態維持剤又は増殖促進剤を、ヒトを含めた哺乳動物の幹細胞に適用することで、幹細胞の未分化状態を維持し、また幹細胞の増殖を促進することができる。本発明に係る幹細胞の未分化状態維持剤又は増殖促進剤を適用する幹細胞としては、本発明の目的に沿うものであれば特に限定されず、例えば胚性の幹細胞(ES細胞);骨髄、血液、皮膚(表皮、真皮、皮下組織)、脂肪、毛包、脳、神経、肝臓、膵臓、腎臓、筋肉やその他の組織に存在する体性の幹細胞;遺伝子導入等により人工的に作製された幹細胞(人工多能性幹細胞:iPS細胞)が挙げられる。好ましくは、本発明に係る幹細胞の未分化状態維持剤又は増殖促進剤は、骨髄、血液、皮膚又は脂肪組織由来の幹細胞に対してより効果を発揮する。例えば、骨髄由来の幹細胞として造血幹細胞が挙げられ、本発明において「造血幹細胞」とは、多能性骨髄系幹細胞及び多能性リンパ系幹細胞を含み、骨髄系細胞(赤血球、血小板、好酸球、好塩基球、好中球、単球等)及びリンパ系細胞(B細胞、T細胞、NK細胞等)への分化が可能な細胞をいう。造血幹細胞は、CD34抗原が陽性で、かつ、CD38抗原が陰性である(CD34+CD38−)ことにより特徴づけられる。ES細胞としては、例えば、着床以前の初期胚を培養することによって樹立されたES細胞、体細胞の核を核移植することによって作製された初期胚を培養することによって樹立されたES細胞、及びそれらのES細胞の染色体上の遺伝子を遺伝子工学の手法を用いて改変したES細胞が挙げられる。このようなES細胞は、例えば、自体公知の方法によって作製することができるが、所定の機関より入手でき、さらには市販品を購入することもできる。また、これらの幹細胞は、初代培養細胞、継代培養細胞又は凍結細胞のいずれであってもよい。 By applying the undifferentiated state-maintaining agent or growth-promoting agent for stem cells according to the present invention to mammalian stem cells including humans, it is possible to maintain the undifferentiated state of stem cells and promote the growth of stem cells. .. The stem cells to which the undifferentiated state-maintaining agent or growth-promoting agent of the stem cells according to the present invention are applied are not particularly limited as long as they meet the object of the present invention, for example, embryonic stem cells (ES cells); bone marrow, blood. , Somatic stem cells present in skin (epidermal, dermal, subcutaneous tissue), fat, hair follicles, brain, nerves, liver, pancreas, kidneys, muscles and other tissues; stem cells artificially produced by gene transfer, etc. (Artificial pluripotent stem cells: iPS cells). Preferably, the undifferentiated state-maintaining agent or growth-promoting agent for stem cells according to the present invention exerts more effect on stem cells derived from bone marrow, blood, skin or adipose tissue. For example, hematopoietic stem cells are mentioned as stem cells derived from bone marrow, and in the present invention, "hematopoietic stem cells" include pluripotent myeloid stem cells and pluripotent lymphoid stem cells, and myeloid cells (erythrocytes, platelets, eosinophils). , Stem cells, neutrophils, monospheres, etc.) and cells capable of differentiating into lymphoid cells (B cells, T cells, NK cells, etc.). Hematopoietic stem cells are characterized by being positive for the CD34 antigen and negative for the CD38 antigen (CD34 + CD38-). Examples of ES cells include ES cells established by culturing early embryos before implantation, and ES cells established by culturing early embryos prepared by nuclear transplantation of somatic cell nuclei. And ES cells in which genes on the chromosomes of those ES cells are modified by using genetic engineering techniques. Such ES cells can be produced, for example, by a method known per se, but can be obtained from a predetermined institution, and a commercially available product can also be purchased. In addition, these stem cells may be either primary cultured cells, subcultured cells, or frozen cells.

さらに、本発明に係る幹細胞の未分化状態維持剤又は増殖促進剤は、幹細胞の分化の方向性及び分化の過程等について同等の特性を持っていれば、全ての哺乳動物由来の幹細胞に応用が可能である。例えば、本発明に係る幹細胞の未分化状態維持剤又は増殖促進剤は、ヒト、サル、マウス、ラット、モルモット、ウサギ、ネコ、イヌ、ウマ、ウシ、ヒツジ、ヤギ、ブタ等の哺乳動物の幹細胞に対して効果を発揮することができる。 Furthermore, the undifferentiated state-maintaining agent or proliferation-promoting agent for stem cells according to the present invention can be applied to stem cells derived from all mammals as long as they have the same characteristics regarding the direction of stem cell differentiation and the process of differentiation. It is possible. For example, the undifferentiated state-maintaining agent or growth-promoting agent for stem cells according to the present invention is a mammalian stem cell such as human, monkey, mouse, rat, guinea pig, rabbit, cat, dog, horse, cow, sheep, goat, or pig. Can be effective against.

本発明に係る幹細胞の未分化状態維持剤又は増殖促進剤の幹細胞への適用は、生体外であっても生体内であってもよく、いずれの場合もその作用を発揮できる。従って、本発明に係る幹細胞の未分化状態維持剤又は増殖促進剤は、その有効量を添加した幹細胞培養用培地にて幹細胞を培養することによって、あるいは、ヒトを含む哺乳動物に投与することによって、幹細胞の未分化状態を維持し、増殖を促進することができる。 The application of the undifferentiated state-maintaining agent or growth-promoting agent for stem cells according to the present invention to stem cells may be in vitro or in vivo, and in either case, the action can be exerted. Therefore, the undifferentiated state-maintaining agent or growth-promoting agent for stem cells according to the present invention can be administered by culturing stem cells in a stem cell culture medium to which an effective amount thereof has been added, or by administering to mammals including humans. , Can maintain the undifferentiated state of stem cells and promote proliferation.

本発明に係る幹細胞の未分化状態維持剤又は増殖促進剤は、有効成分であるハマビシ、ボウフウ、及びアカヤジオウから選択される1種又は2種以上の植物の抽出物が優れた幹細胞の未分化状態維持作用及び増殖促進作用を有するので、皮膚、骨芽、軟骨、筋肉、神経、脂肪、肝臓などの生体内の組織又は臓器の幹細胞に作用して当該組織又は臓器の障害又は損傷を治療、改善、及び予防するのに有効である。また、幹細胞は、加齢などに伴い減少又は機能低下することから、本発明に係る幹細胞の未分化状態維持剤又は増殖促進剤は、上記生体内の組織又は臓器の幹細胞の減少や機能低下に関連する疾患を治療、改善、及び予防するのに有効である。ここで、組織又は臓器の障害又は損傷、幹細胞の減少や機能低下に関連する疾患としては、例えば、皮膚関連では、シワ、タルミ、シミ、くすみ、肌荒れ、皮膚の肥厚、毛穴のひらき、ニキビ痕、創傷、瘢痕、ケロイドなどが挙げられ、薄毛や脱毛などの頭皮や毛髪の損傷も含まれる。また、骨関連では、骨粗しょう症、骨折(脊椎圧迫骨折、大腿骨頚部骨折等)など、軟骨疾患では、変形性関節症、関節リウマチ、椎間板ヘルニアなど、神経関連では、脊髄損傷、顔面神経麻痺、アルツハイマー病、筋萎縮性側索硬化症、パーキンソン病、加齢に伴う記憶低下など、血液関連では、再生不良性貧血、白血病など、心血管関連では心筋梗塞、閉塞性動脈硬化症など、歯科関連では歯周病、歯槽膿漏による歯槽骨損傷など、眼科関連では、網膜色素変性症、加齢黄斑変性症、緑内障など、肝臓・膵臓関連では肝炎、肝硬変、糖尿病などが挙げられるが、これらに限定されない。 The undifferentiated state-maintaining agent or growth-promoting agent for stem cells according to the present invention is an undifferentiated state of stem cells in which one or more plant extracts selected from the active ingredients Hamabishi, Bowfu, and Akayajiou are excellent. Since it has a maintenance effect and a growth promoting effect, it acts on stem cells of tissues or organs in the living body such as skin, osteoblasts, cartilage, muscles, nerves, fats, and livers to treat and improve disorders or damages of the tissues or organs. , And is effective in preventing. In addition, since stem cells decrease or decrease in function with aging, the undifferentiated state-maintaining agent or growth-promoting agent for stem cells according to the present invention causes the decrease or function of stem cells in the above-mentioned tissues or organs in the living body. It is effective in treating, ameliorating, and preventing related diseases. Here, as diseases related to tissue or organ damage or damage, reduction of stem cells or functional deterioration, for example, in the case of skin, wrinkles, tarmi, stains, dullness, rough skin, thickening of the skin, open pores, acne scars, etc. , Wounds, scars, keloids, etc., and also includes scalp and hair damage such as thinning hair and hair loss. In addition, osteoporosis and fractures (spine compression fractures, femoral neck fractures, etc.) are involved in bone-related diseases, and periodontal disease, rheumatoid arthritis, and disc hernia are involved in cartilage diseases. Spinal cord injury and facial nerve palsy are involved in nerve-related diseases. , Alzheimer's disease, muscular atrophic lateral sclerosis, Parkinson's disease, age-related memory loss, etc., blood-related, regenerative anemia, leukemia, etc., cardiovascular-related, myocardial infarction, obstructive arteriosclerosis, etc. Related items include periodontal disease and alveolar bone damage due to alveolar pyorrhea, ophthalmology-related items include retinal pigment degeneration, age-related yellow spot degeneration, and glaucoma, and liver / pancreas-related items include hepatitis, liver cirrhosis, and diabetes. Not limited to.

また、ハマビシ、ボウフウ、及びアカヤジオウから選択される1種又は2種以上の植物の抽出物は、造血幹細胞の増殖促進作用及び未分化状態維持作用を有するので、造血幹細胞の減少又は機能低下に関連する血液及び造血器の疾患又は病態を治療、改善、及び予防するための医薬品として有効である。ここで、造血幹細胞の減少又は機能低下に関連する血液及び造血器の疾患又は病態としては、例えば、鉄欠乏性貧血、巨赤芽球性貧血、溶血性貧血、赤芽球癆、再生不良性貧血、先天性貧血(例えば鎌状赤血球血症)、発作性夜間色素尿症、二次性貧血(感染症、悪性腫瘍、慢性疾患、腎疾患、肝疾患、内分泌性疾患等に伴う貧血)、白血病、骨髄異形性症候群、悪性リンパ腫、多発性骨髄腫、骨髄増殖性疾患(真性多血症・本態性血小板血症・骨髄線維症など)、突発性血小板減少性紫斑病、自己免疫性溶血性貧血のほか、一般的な貧血状態(動悸、息切れ、眩暈、立ち眩み、異嗜症、易疲労感、倦怠感、食欲不振、悪心、頭痛、顔面蒼白、肌のクスミやクマ、耳鳴り、肩こり、口角炎等)などが挙げられるが、これらに限定はされない。また、「造血幹細胞の減少又は機能低下」は、上記の疾患によるものだけではなく、抗癌剤や免疫抑制剤の投与、癌の放射線治療によるものを含む。 In addition, extracts of one or more species of plants selected from Tribulus terrestris, Bofu, and Akayajiou have hematopoietic stem cell proliferation promoting action and undifferentiated state maintaining action, and are therefore associated with a decrease or functional decline of hematopoietic stem cells. It is effective as a drug for treating, ameliorating, and preventing diseases or pathological conditions of blood and hematopoietic organs. Here, as the diseases or pathological conditions of blood and hematopoietic organs related to the decrease or functional deterioration of hematopoietic stem cells, for example, iron deficiency anemia, giant erythroblastic anemia, hemolytic anemia, erythroblastemia, aplastic anemia, etc. Anemia, congenital anemia (eg, sickle erythrocytosis), paroxysmal nocturnal pigmenturia, secondary anemia (anemia associated with infectious diseases, malignant tumors, chronic diseases, renal diseases, liver diseases, endocrine diseases, etc.), Leukemia, myelodysplastic syndrome, malignant lymphoma, multiple myeloma, myeloid proliferative disorders (true polyemia, essential thromboemia, myeloid fibrosis, etc.), idiopathic thrombocytopenic purpura, autoimmune hemolytic disease In addition to anemia, general anemia conditions (movement, shortness of breath, dizziness, dizziness, dizziness, aplastic anemia, easy fatigue, malaise, loss of appetite, nausea, headache, pale face, skin stains and bears, ringing in the ears, stiff shoulders, etc. (Mouth hornitis, etc.), but are not limited to these. In addition, "decrease or functional decline of hematopoietic stem cells" includes not only those caused by the above-mentioned diseases but also those caused by administration of anticancer agents and immunosuppressive agents, and radiotherapy for cancer.

本発明に係る幹細胞の未分化状態維持剤又は増殖促進剤におけるハマビシ、ボウフウ、及びアカヤジオウから選択される1種又は2種以上の植物の抽出物の含有量は、特に限定されないが、抽出物の性状(抽出液、濃縮物、又は乾燥物)により、例えば、0.00001〜100重量%の範囲で適宜設定でき、0.0001〜10重量%が好ましく、0.001〜1重量%であることがより好ましい。 The content of one or more plant extracts selected from Tribulus terrestris, Siler, and Rehmannia glutinosa in the undifferentiated state-maintaining agent or growth-promoting agent for stem cells according to the present invention is not particularly limited, but the extract is not particularly limited. Depending on the properties (extract, concentrate, or dried product), for example, it can be appropriately set in the range of 0.00001 to 100% by weight, preferably 0.0001 to 10% by weight, preferably 0.001 to 1% by weight. Is more preferable.

本発明はまた、幹細胞を、ハマビシ、ボウフウ、及びアカヤジオウから選択される1種又は2種以上の植物の抽出物を含有する培地で培養することで、幹細胞の未分化状態を維持させたまま、幹細胞増殖を促進する方法に関する。換言すれば、本発明に係る方法は、幹細胞を、ハマビシ、ボウフウ、及びアカヤジオウから選択される1種又は2種以上の植物の抽出物を含有する培地で培養する工程を含む、幹細胞の製造方法、幹細胞の未分化状態維持方法、又は幹細胞の増殖促進方法ということができる。 The present invention also maintains the undifferentiated state of the stem cells by culturing the stem cells in a medium containing an extract of one or more plants selected from Tribulus terrestris, Siler, and Rehmannia glutinosa. It relates to a method for promoting stem cell proliferation. In other words, the method according to the present invention comprises a step of culturing stem cells in a medium containing an extract of one or more plants selected from Tribulus terrestris, Siler, and Akayaziou. , A method for maintaining an undifferentiated state of stem cells, or a method for promoting proliferation of stem cells.

本発明に係る方法において、幹細胞の培養には、幹細胞の未分化状態維持及び増殖のために一般的に使用されている培地を用いればよい。例えば、幹細胞の生存及び増殖に必要な成分(無機塩、炭水化物、ホルモン、必須アミノ酸、非必須アミノ酸、ビタミン、脂肪酸)を含む基本培地、具体的には、Dulbecco’s Modified Eagle Medium(D−MEM)、Minimum Essential Medium(MEM)、RPMI 1640、Basal Medium Eagle(BME)、Dulbecco’s Modified Eagle Medium:Nutrient Mixture F−12(D−MEM/F−12)、Glasgow Minimum Essential Medium(Glasgow MEM)、ハンクス液(Hank’s balanced salt solution)等が挙げられる。また、培地に、増殖因子として塩基性線維芽細胞増殖因子(bFGF)及び/又は白血球遊走阻止因子(LIF)を添加してもよい。さらに、必要に応じて、培地は、上皮細胞増殖因子(EGF)、腫瘍壊死因子(TNF)、ビタミン類、インターロイキン類、インスリン、トランスフェリン、ヘパリン、ヘパラン硫酸、コラーゲン、フィブロネクチン、プロゲステロン、セレナイト、B27−サプリメント、N2−サプリメント、ITS−サプリメント、抗生物質等を含有してもよい。 In the method according to the present invention, for culturing stem cells, a medium generally used for maintaining and proliferating the undifferentiated state of stem cells may be used. For example, a basal medium containing components necessary for stem cell survival and proliferation (inorganic salts, carbohydrates, hormones, essential amino acids, non-essential amino acids, vitamins, fatty acids), specifically Dulvecco's Modified Eagle Medium (D-MEM). ), Minimum Essential Medium (MEM), RPMI 1640, Basic Medium Eagle (BME), Dulvecco's Modern Eagle's Medium: Natural MinigemeMideMedium (D-MEM) Hank's balanced salt solution and the like can be mentioned. In addition, basic fibroblast growth factor (bFGF) and / or leukocyte migration inhibitory factor (LIF) may be added to the medium as growth factors. In addition, if desired, the medium is epidermal growth factor (EGF), tumor necrosis factor (TNF), vitamins, interleukins, insulin, transferase, heparin, heparan sulfate, collagen, fibronectin, progesterone, selenite, B27. -Supplement, N2-supplement, ITS-supplement, antibiotics, etc. may be contained.

また、上記の成分以外には、1〜20%の含有率で血清が培地に含まれることが好ましい。しかしながら、血清はロットの違いにより成分が異なり、その効果にバラツキがあるため、ロットチェックを行った後に使用することが好ましい。 In addition to the above components, it is preferable that serum is contained in the medium at a content of 1 to 20%. However, since the components of serum differ depending on the lot and the effect varies, it is preferable to use the serum after performing a lot check.

市販品の培地としては、インビトロジェン製の間葉系幹細胞基礎培地や、三光純薬製の間葉系幹細胞基礎培地、TOYOBO社製のMF培地、Sigma社製のハンクス液(Hank’s balanced salt solution)等を用いることができる。 Commercially available media include Invitrogen's mesenchymal stem cell basal medium, Sanko Pure Chemical's mesenchymal stem cell basal medium, TOYOBO's MF medium, and Sigma's Hanks solution (Hank's balanced salt solution). ) Etc. can be used.

幹細胞の培養に用いる培養器は、幹細胞の培養が可能なものであれば特に限定されないが、例えば、フラスコ、シャーレ、ディッシュ、プレート、チャンバースライド、チューブ、トレイ、培養バッグ、ローラーボトルなどが挙げられる。 The incubator used for culturing stem cells is not particularly limited as long as it can cultivate stem cells, and examples thereof include flasks, petri dishes, dishes, plates, chamber slides, tubes, trays, culture bags, and roller bottles. ..

培養器は、細胞非接着性であっても接着性であってもよく、目的に応じて適宜選択される。細胞接着性の培養器は、細胞との接着性を向上させる目的で、細胞外マトリックス等による細胞支持用基質などで処理したものを用いてもよい。細胞支持用基質としては、例えば、コラーゲン、ゼラチン、ポリ−L−リジン、ポリ−D−リジン、ラミニン、フィブロネクチンなどが挙げられる。 The incubator may be cell non-adhesive or adhesive, and is appropriately selected depending on the intended purpose. As the cell adhesion incubator, one treated with a cell support substrate or the like using an extracellular matrix or the like may be used for the purpose of improving the adhesion to cells. Examples of the cell support substrate include collagen, gelatin, poly-L-lysine, poly-D-lysine, laminin, fibronectin and the like.

幹細胞培養に使用される培地に対するハマビシ、ボウフウ、及びアカヤジオウから選択される1種又は2種以上の植物の抽出物の添加濃度は、上述の本発明に係る幹細胞の未分化状態維持剤又は増殖促進剤におけるハマビシ、ボウフウ、及びアカヤジオウから選択される1種又は2種以上の植物の抽出物の含有量に準じて適宜決定することができるが、ハマビシ、ボウフウ、及びアカヤジオウから選択される1種又は2種以上の植物の抽出物の乾燥物に換算して、例えば10〜10000μg/mL、好ましくは100〜5000μg/mLの濃度が挙げられる。また、幹細胞の培養期間中、これらの抽出物を定期的に培地に添加してもよい。 The addition concentration of one or more plant extracts selected from Tribulus terrestris, Siler, and Rehmannia glutinosa to the medium used for stem cell culture is the above-mentioned undifferentiated state-maintaining agent or growth promoting of stem cells according to the present invention. It can be appropriately determined according to the content of the extract of one or more plants selected from Tribulus terrestris, Siler, and Rehmannia glutinosa in the agent, but one species or one selected from Tribulus terrestris, Siler, and Rehmannia glutinosa. In terms of a dried product of extracts of two or more kinds of plants, for example, a concentration of 10 to 10000 μg / mL, preferably 100 to 5000 μg / mL can be mentioned. In addition, these extracts may be added to the medium on a regular basis during the stem cell culture period.

幹細胞の培養条件は、幹細胞の培養に用いられる通常の条件に従えばよく、特別な制御は必要ではない。例えば、培養温度は、特に限定されるものではないが約30〜40℃、好ましくは36〜37℃である。COガス濃度は、例えば約1〜10%、好ましくは約2〜5%である。なお、培地の交換は2〜3日に1回行うことが好ましく、毎日行うことがより好ましい。前記培養条件は、幹細胞が生存及び増殖可能な範囲で適宜変動させて設定することもできる。 The stem cell culture conditions may follow the usual conditions used for stem cell culture, and no special control is required. For example, the culture temperature is not particularly limited, but is about 30 to 40 ° C, preferably 36 to 37 ° C. The CO 2 gas concentration is, for example, about 1-10%, preferably about 2-5%. The medium is preferably changed once every 2 to 3 days, and more preferably every day. The culture conditions can be appropriately varied and set within a range in which stem cells can survive and proliferate.

幹細胞の未分化状態維持は、例えば、本発明に係る幹細胞の未分化状態維持剤の非存在下で培養した幹細胞と比較して、本発明に係る幹細胞の未分化状態維持剤の存在下で培養した該幹細胞において幹細胞未分化マーカー遺伝子の発現レベルがmRNAレベル又はタンパク質レベルで培養開始時の発現レベルと同程度のレベルに有意に維持されているか否かで評価することができる。幹細胞未分化マーカー遺伝子としては、例えばNanog遺伝子(Cell Res. 2007 Jan; 17(1):42−9. Review. Nanog and transcriptional networks in embryonic stem cell pluripotency. Pan G, Thomson JA.)等が挙げられる。 For maintaining the undifferentiated state of stem cells, for example, the stem cells are cultured in the presence of the undifferentiated state maintaining agent of the stem cells according to the present invention, as compared with the stem cells cultured in the absence of the undifferentiated state maintaining agent of the stem cells according to the present invention. It can be evaluated whether or not the expression level of the stem cell undifferentiated marker gene is significantly maintained at the mRNA level or the protein level at the same level as the expression level at the start of culture in the stem cells. Examples of the stem cell undifferentiated marker gene include the Nanog gene (Cell Res. 2007 Jan; 17 (1): 42-9. Review. Nanog and transcriptional network, Embryonic stem Cell Group, etc. ..

幹細胞未分化マーカー遺伝子発現レベルの測定方法としては、mRNAレベルでは、例えば幹細胞未分化マーカー遺伝子に特異的なプライマーやプローブを用いたRT−PCR、定量PCRやノーザンブロッティング等の方法が挙げられ、また、タンパク質レベルでは、例えば幹細胞未分化マーカー遺伝子によりコードされるタンパク質に特異的な抗体を用いたELISA、フローサイトメトリー、ウエスタンブロッティング等の免疫学的方法が挙げられる。 Examples of the method for measuring the expression level of the stem cell undifferentiated marker gene include RT-PCR using primers and probes specific for the stem cell undifferentiated marker gene, quantitative PCR, Northern blotting, and the like at the mRNA level. At the protein level, examples thereof include immunological methods such as ELISA, flow cytometry, and Western blotting using an antibody specific for a protein encoded by a stem cell undifferentiated marker gene.

発現レベルの測定の結果、培養開始時(100%未分化状態)の幹細胞における幹細胞未分化マーカー遺伝子の発現レベルと本発明の幹細胞の未分化状態維持剤の存在下で所定時間培養後の幹細胞における幹細胞未分化マーカー遺伝子の発現レベルとの相対比が、本発明の幹細胞の未分化状態維持剤の非存在下で培養した場合の同相対比(コントロール)よりも大きい場合に幹細胞の未分化状態を維持できたと判定することができる。 As a result of measuring the expression level, the expression level of the stem cell undifferentiated marker gene in the stem cell at the start of culturing (100% undifferentiated state) and the stem cell after culturing for a predetermined time in the presence of the undifferentiated state maintaining agent of the stem cell of the present invention. When the relative ratio to the expression level of the stem cell undifferentiated marker gene is larger than the relative ratio (control) when the stem cell of the present invention is cultured in the absence of the undifferentiated state maintaining agent, the undifferentiated state of the stem cell is defined. It can be determined that the maintenance was possible.

また、幹細胞の増殖促進は、例えば、本発明に係る幹細胞の増殖促進剤の非存在下で培養した幹細胞と比較して、本発明に係る幹細胞の増殖促進剤の存在下で培養した該幹細胞の細胞数が有意に増加されているか否かで評価することができる。細胞数の測定は、例えば、MTT法やWST法などにより、市販の細胞数測定キットを用いて行うことができる。測定の結果、培養開始時の幹細胞の細胞数と本発明の幹細胞の増殖促進剤の存在下で所定時間培養後の幹細胞の細胞数との相対比が、本発明の幹細胞の増殖促進剤の非存在下で培養した場合の同相対比(コントロール)よりも大きい場合に幹細胞の増殖を促進できたと判定することができる。 Further, the promotion of stem cell proliferation is carried out, for example, as compared with the stem cells cultured in the absence of the stem cell proliferation promoter according to the present invention, the stem cells cultured in the presence of the stem cell proliferation promoter according to the present invention. It can be evaluated by whether or not the number of cells is significantly increased. The cell number can be measured by using a commercially available cell number measurement kit by, for example, the MTT method or the WST method. As a result of the measurement, the relative ratio between the number of stem cells at the start of culturing and the number of stem cells after culturing for a predetermined time in the presence of the stem cell growth promoter of the present invention is not the stem cell growth promoter of the present invention. When it is larger than the same relative ratio (control) when cultured in the presence, it can be determined that the proliferation of stem cells could be promoted.

上記の本発明に係る方法により調製された幹細胞は移植材料(細胞移植剤)として用いることができ、従来の骨髄移植又は臍帯血移植と同一の方法で実施できる。 The stem cells prepared by the above method according to the present invention can be used as a transplant material (cell transplant agent), and can be carried out by the same method as conventional bone marrow transplantation or cord blood transplantation.

上記の本発明に係る幹細胞の未分化状態維持剤又は増殖促進剤あるいは本発明に係る方法に準じて、ハマビシ、ボウフウ、及びアカヤジオウから選択される1種又は2種以上の植物の抽出物を、単独で、あるいは培地と別々に又は培地と混合し、幹細胞の未分化状態維持又は増殖促進のための試薬キットとして提供することもできる。当該キットは、必要に応じて取扱い説明書等を含むことができる。あるいは、ハマビシ、ボウフウ、及びアカヤジオウから選択される1種又は2種以上の植物の抽出物を培地と混合し、幹細胞の未分化状態維持又は増殖促進用培地として提供することもできる。 An extract of one or more plants selected from Tribulus terrestris, Siler, and Rehmannia glutinosa according to the above-mentioned undifferentiated state-maintaining agent or growth promoter of stem cells according to the present invention or the method according to the present invention. It can also be provided alone or separately from the medium or mixed with the medium as a reagent kit for maintaining the undifferentiated state of stem cells or promoting proliferation. The kit may include an instruction manual or the like, if necessary. Alternatively, an extract of one or more plants selected from Tribulus terrestris, Siler, and Rehmannia glutinosa can be mixed with a medium and provided as a medium for maintaining an undifferentiated state of stem cells or promoting proliferation.

本発明に係る上記の幹細胞の未分化状態維持剤又は増殖促進剤を生体内に投与する場合は、そのまま投与することも可能であるが、本発明の効果を損なわない範囲で適当な添加物とともに化粧品、医薬部外品、医薬品、飲食品等の各種組成物に配合して提供することができる。なお、本発明の医薬品には、動物に用いる薬剤、即ち獣医薬も包含されるものとする。 When the above-mentioned undifferentiated state-maintaining agent or growth-promoting agent for stem cells according to the present invention is administered in vivo, it can be administered as it is, but together with an appropriate additive as long as the effect of the present invention is not impaired. It can be blended and provided in various compositions such as cosmetics, quasi-drugs, pharmaceuticals, and foods and drinks. The pharmaceutical product of the present invention also includes a drug used for animals, that is, a veterinary drug.

本発明に係る幹細胞の未分化状態維持剤又は増殖促進剤を化粧品や医薬部外品に配合する場合は、その剤形は、水溶液系、可溶化系、乳化系、粉末系、粉末分散系、油液系、ゲル系、軟膏系、エアゾール系、水−油二層系、又は水−油−粉末三層系等のいずれでもよい。また、当該化粧品や医薬部外品は、幹細胞の未分化状態維持剤又は増殖促進剤とともに、皮膚外用組成物において通常使用されている各種成分、添加剤、基剤等をその種類に応じて選択し、適宜配合し、当分野で公知の手法に従って製造することができる。その形態は、液状、乳液状、クリーム状、ゲル状、ペースト状、スプレー状等のいずれであってもよい。皮膚外用組成物の配合成分としては、例えば、油脂類(オリーブ油、ヤシ油、月見草油、ホホバ油、ヒマシ油、硬化ヒマシ油等)、ロウ類(ラノリン、ミツロウ、カルナウバロウ等)、炭化水素類(流動パラフィン、スクワレン、スクワラン、ワセリン等)、脂肪酸類(ラウリン酸、ミリスチン酸、パルミチン酸、ステアリン酸、ベヘニン酸等)、高級アルコール類(ミリスチルアルコール、セタノール、セトステアリルアルコール、ステアリルアルコール、ベヘニルアルコール等)、エステル類(ミリスチン酸イソプロピル、パルミチン酸イソプロピル、オクタン酸セチル、トリオクタン酸グリセリン、ミリスチン酸オクチルドデシル、ステアリン酸オクチル、ステアリン酸ステアリル等)、有機酸類(クエン酸、乳酸、α-ヒドロキシ酢酸、ピロリドンカルボン酸等)、糖類(マルチトール、ソルビトール、キシロビオース、N-アセチル-D-グルコサミン等)、蛋白質及び蛋白質の加水分解物、アミノ酸類及びその塩、ビタミン類、植物・動物抽出成分、種々の界面活性剤、保湿剤、紫外線吸収剤、抗酸化剤、安定化剤、防腐剤、殺菌剤、香料等が挙げられる。 When the undifferentiated state-maintaining agent or growth-promoting agent for stem cells according to the present invention is blended in cosmetics or non-pharmaceutical products, the dosage form is an aqueous solution system, a solubilization system, an emulsification system, a powder system, a powder dispersion system, It may be any of oil-liquid type, gel type, ointment type, aerosol type, water-oil two-layer system, water-oil-powder three-layer system and the like. In addition, for the cosmetics and quasi-drugs, various components, additives, bases and the like usually used in the external composition for skin are selected according to the type, together with the undifferentiated state maintaining agent or growth promoting agent for stem cells. However, it can be appropriately blended and produced according to a method known in the art. The form may be any of liquid, emulsion, cream, gel, paste, spray and the like. Examples of the components of the composition for external use on the skin include fats and oils (olive oil, palm oil, evening primrose oil, jojoba oil, castor oil, hardened castor oil, etc.), waxes (lanolin, honeybee, carnauba wax, etc.), and hydrocarbons (carnauba wax, etc.). Liquid paraffin, squalane, squalane, vaseline, etc.), fatty acids (lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, etc.), higher alcohols (myristyl alcohol, cetanol, cetostearyl alcohol, stearyl alcohol, behenyl alcohol, etc.) , Esters (isopropyl myristate, isopropyl palmitate, cetyl octanoate, glycerin trioctanoate, octyldodecyl myristate, octyl stearate, stearyl stearate, etc.), organic acids (citrate, lactic acid, α-hydroxyacetic acid, pyrrolidone carboxylic acid) Acids, etc.), sugars (martitol, sorbitol, xylobiose, N-acetyl-D-glucosamine, etc.), proteins and hydrolyzates of proteins, amino acids and their salts, vitamins, plant / animal extracts, various surface activities Examples include agents, moisturizers, ultraviolet absorbers, antioxidants, stabilizers, preservatives, bactericides, fragrances and the like.

化粧品や医薬部外品の種類としては、例えば、化粧水、乳液、ジェル、美容液、一般クリーム、日焼け止めクリーム、パック、マスク、洗顔料、化粧石鹸、ファンデーション、おしろい、浴用剤、ボディローション、ボディシャンプー、ヘアシャンプー、ヘアコンディショナー、育毛剤等が挙げられる。 Types of cosmetics and non-pharmaceutical products include, for example, lotion, milky lotion, gel, beauty essence, general cream, sunscreen cream, facial mask, mask, face wash, cosmetic soap, foundation, face powder, bathing agent, body lotion, etc. Examples include body shampoos, hair shampoos, hair conditioners, and hair restorers.

本発明に係る幹細胞の未分化状態維持剤又は増殖促進剤を医薬品に配合する場合は、薬理学的及び製剤学的に許容しうる添加物と混合し、患部に適用するのに適した製剤形態の各種製剤に製剤化することができる。薬理学的及び製剤学的に許容しうる添加物としては、その剤形、用途に応じて、適宜選択した製剤用基材や担体、賦形剤、希釈剤、結合剤、滑沢剤、コーティング剤、崩壊剤又は崩壊補助剤、安定化剤、保存剤、防腐剤、増量剤、分散剤、湿潤化剤、緩衝剤、溶解剤又は溶解補助剤、等張化剤、pH調節剤、噴射剤、着色剤、甘味剤、矯味剤、香料等を適宜添加し、公知の種々の方法にて経口又は非経口的に全身又は局所投与することができる各種製剤形態に調製すればよい。本発明の医薬品を上記の各形態で提供する場合、通常当業者に用いられる製法、たとえば日本薬局方の製剤総則[2]製剤各条に示された製法等により製造することができる。 When the undifferentiated state-maintaining agent or growth-promoting agent for stem cells according to the present invention is blended with a pharmaceutical product, it is mixed with a pharmacologically and pharmaceutically acceptable additive and is suitable for application to an affected area. Can be formulated into various formulations of. Pharmacologically and pharmaceutically acceptable additives include formulation substrates and carriers, excipients, diluents, binders, preservatives, and coatings that are appropriately selected according to the dosage form and application. Agents, disintegrants or disintegrants, stabilizers, preservatives, preservatives, bulking agents, dispersants, wetting agents, buffers, solubilizers or solubilizers, isotonic agents, pH regulators, propellants , Coloring agents, sweeteners, flavoring agents, fragrances and the like may be appropriately added to prepare various formulations that can be orally or parenterally administered systemically or topically by various known methods. When the pharmaceutical product of the present invention is provided in each of the above forms, it can be produced by a manufacturing method usually used by those skilled in the art, for example, the manufacturing method shown in each article of the general formulation [2] formulation of the Japanese Pharmacopoeia.

本発明の医薬品の形態としては、特に制限されるものではないが、例えば錠剤、糖衣錠剤、カプセル剤、トローチ剤、顆粒剤、散剤、液剤、丸剤、乳剤、シロップ剤、懸濁剤、エリキシル剤などの経口剤、注射剤(例えば、皮下注射剤、静脈内注射剤、筋肉内注射剤、腹腔内注射剤)、点滴剤、座剤、軟膏剤、ローション剤、点眼剤、噴霧剤、経皮吸収剤、経粘膜吸収剤、貼付剤などの非経口剤などが挙げられる。また、使用する際に再溶解させる乾燥生成物にしてもよく、注射用製剤の場合は単位投与量アンプル又は多投与量容器の状態で提供される。 The form of the pharmaceutical product of the present invention is not particularly limited, but for example, tablets, sugar-coated tablets, capsules, troches, granules, powders, liquids, pills, emulsions, syrups, suspending agents, and elixirs. Oral agents such as drugs, injections (for example, subcutaneous injections, intravenous injections, intramuscular injections, intraperitoneal injections), infusions, suppositories, ointments, lotions, eye drops, sprays, trans. Examples include parenteral agents such as skin absorbents, transmucosal absorbents, and patches. It may also be a dry product that is redissolved upon use, and in the case of injectable formulations, it is provided in the form of unit dose ampoules or multidose containers.

本発明に係る幹細胞の未分化状態維持剤又は増殖促進剤を、前記皮膚関連の損傷や疾患を治療、改善、及び予防するための医薬品として用いる場合に適した形態は外用製剤であり、例えば、軟膏剤、クリーム剤、ゲル剤、液剤、貼付剤(パップ剤、プラスター剤)、フォーム剤、スプレー剤、噴霧剤などが挙げられる。軟膏剤は、均質な半固形状の外用製剤をいい、油脂性軟膏、乳剤性軟膏、水溶性軟膏を含む。ゲル剤は、水不溶性成分の抱水化合物を水性液に懸濁した外用製剤をいう。液剤は、液状の外用製剤をいい、ローション剤、懸濁剤、乳剤、リニメント剤等を含む。 A suitable form for using the undifferentiated state-maintaining agent or growth-promoting agent for stem cells according to the present invention as a pharmaceutical product for treating, ameliorating, or preventing the skin-related damage or disease is an external preparation, for example. Examples include ointments, creams, gels, liquids, patches (pups, plasters), foams, sprays, sprays and the like. The ointment refers to a homogeneous semi-solid external preparation, and includes an oily ointment, an emulsion ointment, and a water-soluble ointment. A gel agent refers to an external preparation in which a water-holding compound, which is a water-insoluble component, is suspended in an aqueous solution. The liquid agent refers to a liquid external preparation, and includes a lotion agent, a suspension agent, an emulsion, a liniment agent, and the like.

本発明の医薬品は、上記疾患の発症を抑制する予防薬として、及び/又は、正常な状態に改善する治療薬として機能する。本発明の医薬品の有効成分は、天然物由来であるため、非常に安全性が高く副作用がないため、前述の疾患の治療、改善、及び予防用医薬として用いる場合、ヒト、マウス、ラット、ウサギ、イヌ、ネコ等の哺乳動物に対して広い範囲の投与量で経口的に又は非経口的に投与することができる。 The pharmaceutical product of the present invention functions as a preventive agent for suppressing the onset of the above-mentioned diseases and / or as a therapeutic agent for improving a normal state. Since the active ingredient of the pharmaceutical product of the present invention is derived from a natural product, it is extremely safe and has no side effects. Therefore, when it is used as a therapeutic, ameliorating, or preventive drug for the above-mentioned diseases, humans, mice, rats, and rabbits. , Dogs, cats and other mammals can be administered orally or parenterally in a wide range of doses.

本発明の化粧品、医薬品、医薬部外品における幹細胞の未分化状態維持剤又は増殖促進剤の含有量は特に限定されないが、製剤(組成物)全重量に対して、ハマビシ、ボウフウ、及びアカヤジオウから選択される1種又は2種以上の植物の抽出物の乾燥物に換算して、0.001〜30重量%が好ましく、0.01〜10重量%がより好ましい。上記の量があくまで例示であって、組成物の種類や形態、一般的な使用量、効能・効果などを考慮して適宜設定・調整すればよい。また、製剤化における有効成分の添加法については、予め加えておいても、製造途中で添加してもよく、作業性を考えて適宜選択すればよい。 The content of the undifferentiated state-maintaining agent or growth-promoting agent for stem cells in the cosmetics, pharmaceuticals, and quasi-drugs of the present invention is not particularly limited, but from Tribulus terrestris, Siler, and Rehmannia glutinosa with respect to the total weight of the preparation (composition). In terms of a dried product of one or more selected plant extracts, 0.001 to 30% by weight is preferable, and 0.01 to 10% by weight is more preferable. The above amounts are merely examples, and may be appropriately set and adjusted in consideration of the type and form of the composition, general usage amount, efficacy / effect, and the like. Further, the method of adding the active ingredient in the formulation may be added in advance or may be added during the production, and may be appropriately selected in consideration of workability.

また、本発明に係る幹細胞の未分化状態維持剤又は増殖促進剤は、飲食品にも配合できる。また、本発明において、飲食品とは、一般的な飲食品のほか、医薬品以外で健康の維持や増進を目的として摂取できる食品、例えば、健康食品、機能性食品、保健機能食品、又は特別用途食品を含む意味で用いられる。健康食品には、栄養補助食品、健康補助食品、サプリメント等の名称で提供される食品を含む。保健機能食品は食品衛生法又は健康増進法により定義され、特定の保健の効果や栄養成分の機能、疾病リスクの低減などを表示できる、特定保健用食品及び栄養機能食品、ならびに科学的根拠に基づいた機能性について消費者庁長官に届け出た内容を表示できる機能性表示食品が含まれる。また特別用途食品には、特定の対象者や特定の疾患を有する患者に適する旨を表示する病者用食品、高齢者用食品、乳児用食品、妊産婦用食品等が含まれる。幹細胞が造血幹細胞である場合は、本剤は、特に高齢者、妊産婦、月経や出血傾向を伴う疾病(胃潰瘍、十二指腸潰瘍、胃腸のポリープや癌、痔など)時における貧血や貧血に伴う諸症状の改善及び予防のための健康食品等に好適に用いることができる。ここで、飲食品に付される特定の保健の効果や栄養成分の機能等の表示は、製品の容器、包装、説明書、添付文書などの表示物、製品のチラシやパンフレット、新聞や雑誌等の製品の広告などにすることができる。 In addition, the undifferentiated state-maintaining agent or growth-promoting agent for stem cells according to the present invention can also be blended in foods and drinks. Further, in the present invention, the food and drink are not only general foods and drinks but also foods other than pharmaceuticals that can be ingested for the purpose of maintaining or improving health, such as health foods, functional foods, health functional foods, or special uses. It is used to include food. Health foods include foods provided under the names of dietary supplements, dietary supplements, supplements and the like. Health functional foods are defined by the Food Hygiene Law or the Health Promotion Law, and are based on specified health foods and nutritionally functional foods that can display specific health effects, functions of nutritional components, reduction of disease risk, etc., and scientific evidence. Includes foods with functional claims that can display the contents notified to the Commissioner of the Consumer Affairs Agency. In addition, special-purpose foods include foods for the sick, foods for the elderly, foods for babies, foods for pregnant women, etc. that indicate that they are suitable for a specific target person or a patient having a specific disease. If the stem cells are hematopoietic stem cells, this drug may cause anemia or symptoms associated with anemia, especially in elderly people, pregnant women, and diseases associated with menstruation and bleeding tendency (gastric ulcer, duodenal ulcer, gastrointestinal polyps and cancer, hemorrhoids, etc.). It can be suitably used for health foods and the like for improvement and prevention of. Here, the indications such as specific health effects and functions of nutritional components attached to foods and drinks are indications such as product containers, packaging, manuals, package inserts, product leaflets and pamphlets, newspapers and magazines, etc. It can be used as an advertisement for a product of.

飲食品の形態は、食用に適した形態、例えば、固形状、液状、顆粒状、粒状、粉末状、カプセル状、クリーム状、ペースト状のいずれであってもよい。特に、上記の健康食品等の場合の形状としては、例えば、タブレット状、丸状、カプセル状、粉末状、顆粒状、細粒状、トローチ状、液状(シロップ状、乳状、懸濁状を含む)等が好ましい。 The form of the food or drink may be any of edible forms such as solid, liquid, granular, granular, powdery, capsule-like, cream-like, and paste-like. In particular, in the case of the above-mentioned health foods, for example, tablets, rounds, capsules, powders, granules, fine granules, troches, and liquids (including syrup, milky, and suspension) Etc. are preferable.

飲食品の種類としては、パン類、麺類、菓子類、乳製品、水産・畜産加工食品、油脂及び油脂加工食品、調味料、各種飲料(清涼飲料、炭酸飲料、美容ドリンク、栄養飲料、果実飲料、乳飲料など)及び該飲料の濃縮原液及び調整用粉末等が挙げられるが、これらに限定はされない。 The types of foods and drinks include breads, noodles, confectionery, dairy products, processed marine and livestock foods, fats and oils, processed fats and oils, seasonings, and various beverages (soft drinks, carbonated drinks, beauty drinks, nutritional drinks, fruit drinks). , Milk beverages, etc.), concentrated stock solutions of the beverages, preparation powders, etc., but are not limited thereto.

本発明の飲食品は、その種類に応じて通常使用される添加物を適宜配合してもよい。添加物としては、食品衛生法上許容されうる添加物であればいずれも使用できるが、例えば、ブドウ糖、ショ糖、果糖、異性化液糖、アスパルテーム、ステビア等の甘味料;クエン酸、リンゴ酸、酒石酸等の酸味料;デキストリン、デンプン等の賦形剤;結合剤、希釈剤、香料、着色料、緩衝剤、増粘剤、ゲル化剤、安定剤、保存剤、乳化剤、分散剤、懸濁化剤、防腐剤などが挙げられる。 The food and drink of the present invention may appropriately contain additives that are usually used depending on the type of food and drink. As the additive, any additive that is acceptable under the Food Sanitation Law can be used, and for example, sweeteners such as starch, sucrose, fructose, isomerized liquid sugar, aspartame, and stevia; citric acid, malic acid, etc. , Acidulants such as citric acid; Excipients such as dextrin and starch; Binding agents, diluents, fragrances, colorants, buffers, thickeners, gelling agents, stabilizers, preservatives, emulsifiers, dispersants, suspensions Examples include turbidants and preservatives.

本発明の飲食品が一般的な飲食品の場合は、その飲食品の通常の製造工程においてハマビシ、ボウフウ、及びアカヤジオウから選択される1種又は2種以上の植物の抽出物を添加する工程を含めることによって製造することができる。また健康食品の場合は、前記の医薬品の製造方法に準じればよく、例えば、タブレット状のサプリメントでは、ハマビシ、ボウフウ、及びアカヤジオウから選択される1種又は2種以上の植物の抽出物に、賦形剤等の添加物を添加、混合し、打錠機等で圧力をかけて成形することにより製造することができる。また、必要に応じてその他の材料(例えば、ビタミンC、ビタミンB、ビタミンB等のビタミン類、カルシウムなどのミネラル類、食物繊維等)を添加することもできる。 When the food or drink of the present invention is a general food or drink, a step of adding an extract of one or more kinds of plants selected from Tribulus terrestris, Siler, and Rehmannia glutinosa in the normal manufacturing process of the food and drink is performed. It can be manufactured by including it. In the case of health foods, the above-mentioned method for manufacturing pharmaceutical products may be applied. For example, in the case of tablet-shaped supplements, one or more plant extracts selected from Tribulus terrestris, Siler, and Akayaziou may be used. It can be produced by adding and mixing additives such as excipients and applying pressure with a tableting machine or the like to form the product. Further, other materials (e.g., vitamin C, vitamin B 2, vitamin such as vitamin B 6, minerals such as calcium, fiber, etc.) optionally may be added.

本発明の飲食品におけるハマビシ、ボウフウ、及びアカヤジオウから選択される1種又は2種以上の植物の抽出物の配合量は、幹細胞の未分化状態維持効果及び増殖促進効果を発揮できる量であればよいが、対象飲食品の一般的な摂取量、飲食品の形態、効能・効果、呈味性、嗜好性及びコストなどを考慮して適宜設定すればよい。 The blending amount of the extract of one or more kinds of plants selected from Tribulus terrestris, Siler, and Rehmannia glutinosa in the food and drink of the present invention is an amount capable of exerting the undifferentiated state maintaining effect and the growth promoting effect of stem cells. However, it may be appropriately set in consideration of the general intake amount of the target food or drink, the form of the food or drink, the efficacy / effect, the taste, the palatability, the cost, and the like.

以下、実施例を用いて本発明をより詳細に説明するが、本発明の技術的範囲はこれら実施例に限定されるものではない。 Hereinafter, the present invention will be described in more detail with reference to Examples, but the technical scope of the present invention is not limited to these Examples.

[実施例1]ハマビシ、ボウフウ、及びアカヤジオウの抽出物の製造例
以下に、ハマビシ、ボウフウ、及びアカヤジオウを用いた溶媒抽出物の製造例を示す。
[Example 1] Production example of extract of Tribulus terrestris, Siler, and Rehmannia glutinosa The following shows an example of production of a solvent extract using Tribulus terrestris, Siler, and Rehmannia glutinosa.

(製造例1)ハマビシの熱水抽出物の製造
ハマビシの未熟果の乾燥物100gに精製水800mLを加え、95〜100℃で2時間抽出した後、濾過し、その濾液を濃縮し、凍結乾燥してハマビシの熱水抽出物を5.2g得た。
(Production Example 1) Production of hot water extract of Hamabishi Add 800 mL of purified water to 100 g of dried unripe fruit of Hamabishi, extract at 95-100 ° C for 2 hours, filter, concentrate the filtrate, and freeze-dry. Then, 5.2 g of a hot water extract of Hamabishi was obtained.

(製造例2)ハマビシのエタノール抽出物の製造
ハマビシの未熟果の乾燥物100gにエタノール1Lを加え、常温で7日間抽出した後、濾過し、その濾液を濃縮乾固して、ハマビシのエタノール抽出物を5.3g得た。
(Production Example 2) Production of Ethanol Extract of Tribulus terrestris Add 1 L of ethanol to 100 g of dried immature fruit of Tribulus terrestris, extract at room temperature for 7 days, filter, concentrate and dry the filtrate, and extract ethanol of Tribulus terrestris. We obtained 5.3 g of the product.

(製造例3)ボウフウの熱水抽出物の製造
ボウフウの根の乾燥物100gに精製水800mLを加え、95〜100℃で2時間抽出した後、濾過し、その濾液を濃縮し、凍結乾燥してボウフウの熱水抽出物を5.5g得た。
(Production Example 3) Production of hot water extract of Boufu Add 800 mL of purified water to 100 g of dried Bofu root, extract at 95-100 ° C for 2 hours, filter, concentrate the filtrate, and freeze-dry. To obtain 5.5 g of a hot water extract of Bowfu.

(製造例4)ボウフウのエタノール抽出物の製造
ボウフウの根の乾燥物100gにエタノール1Lを加え、常温で7日間抽出した後、濾過し、その濾液を濃縮乾固して、ボウフウのエタノール抽出物を4.3g得た。
(Production Example 4) Production of Ethanol Extract of Siler Add 1 L of ethanol to 100 g of dried Siler root, extract at room temperature for 7 days, filter, concentrate and dry the filtrate, and ethanol extract of Siler. Was obtained in an amount of 4.3 g.

(製造例5)アカヤジオウの熱水抽出物の製造
アカヤジオウの根の乾燥物100gに精製水800mLを加え、95〜100℃で2時間抽出した後、濾過し、その濾液を濃縮し、凍結乾燥してアカヤジオウの熱水抽出物を5.5g得た。
(Production Example 5) Production of hot water extract of Akayaziou Add 800 mL of purified water to 100 g of dried Akayaziou root, extract at 95-100 ° C for 2 hours, filter, concentrate the filtrate, and freeze-dry. 5.5 g of a hot water extract of Akayaziou was obtained.

(製造例6)アカヤジオウのエタノール抽出物の製造
アカヤジオウの根の乾燥物100gにエタノール1Lを加え、常温で7日間抽出した後、濾過し、その濾液を濃縮乾固して、アカヤジオウのエタノール抽出物を4.3g得た。
(Production Example 6) Production of Ethanol Extract of Rehmannia glutinosa Add 1 L of ethanol to 100 g of dried Rehmannia glutinosa root, extract at room temperature for 7 days, filter, concentrate and dry the filtrate, and ethanol extract of Rehmannia glutinosa. Was obtained in an amount of 4.3 g.

(製造例7)ハマビシ、ボウフウ、アカヤジオウの混合物の熱水抽出物の製造
ハマビシの未熟果の乾燥物、ボウフウの根の乾燥物、及びアカヤジオウの根の乾燥物を等量ずつ混合した混合物100gに精製水800mLを加え、95〜100℃で2時間抽出した後、濾過し、その濾液を濃縮し、凍結乾燥して生薬混合物の熱水抽出物を5.1g得た。
(Production Example 7) Production of hot water extract of a mixture of Hamabishi, Bowfu, and Akayajiou To 100 g of a mixture of equal amounts of dried hamanbishi fruit, dried bowhu root, and dried red sardine root. After adding 800 mL of purified water and extracting at 95 to 100 ° C. for 2 hours, the mixture was filtered, the filtrate was concentrated, and lyophilized to obtain 5.1 g of a hot water extract of a crude drug mixture.

(製造例8)ハマビシ、ボウフウ、アカヤジオウの混合物のエタノール抽出物の製造
ハマビシの未熟果の乾燥物、ボウフウの根の乾燥物、及びアカヤジオウの根の乾燥物を等量ずつ混合した混合物100gにエタノール1Lを加え、常温で7日間抽出した後、濾過し、その濾液を濃縮乾固して、凍結乾燥して生薬混合物のエタノール抽出物を5.6g得た。
(Production Example 8) Production of Ethanol Extract of Mixture of Hamabishi, Bowfu, and Akayaziou Ethanol in 100 g of a mixture of equal amounts of dried unripe fruit of Hamabishi, dried root of Bowfu, and dried root of Akayaziou. 1 L was added, and the mixture was extracted at room temperature for 7 days, filtered, and the filtrate was concentrated to dryness and freeze-dried to obtain 5.6 g of an ethanol extract of the crude drug mixture.

[実施例2]ハマビシ、ボウフウ、アカヤジオウの抽出物の幹細胞に対する増殖促進効果及び未分化状態維持効果の評価
以下に、実施例1において製造したハマビシ、ボウフウ、アカヤジオウの抽出物を用いた、幹細胞に対する増殖促進効果及び未分化状態維持効果の実験例とその結果を示す。
[Example 2] Evaluation of growth promoting effect and undifferentiated state maintaining effect of Tribulus terrestris, Siler, and Akayaziou extracts on stem cells The following is an evaluation of stem cells using the Tribulus terrestris, Siler, and Akayaziou extracts produced in Example 1. Experimental examples of growth promoting effect and undifferentiated state maintaining effect and their results are shown.

(実験例1)幹細胞に対する増殖促進効果の評価
ヒト幹細胞培養液(TOYOBO社製)を用いて培養したヒト成体幹細胞(DSファーマバイオメディカル社製)を、6cmディッシュに3x10個播種し、被験物質(製造例1のハマビシの抽出物、製造例3のボウフウの抽出物、製造例5のアカヤジオウの抽出物、製造例7のハマビシ、ボウフウ、及びアカヤジオウの混合物の抽出物)を最終濃度が1250μg/mL、2500μg/mL、5000μg/mLになるように添加し、3日間培養を続けた。
(Experimental Example 1) Evaluation of Proliferation-Promoting Effect on Stem Cells Adult adult stem cells (manufactured by DS Pharma Biomedical) cultured using a human stem cell culture medium (manufactured by TOYOBO) were seeded in 3x10 5 pieces in a 6 cm dish, and the test substance was used. (Extract of Tribulus terrestris of Production Example 1, Extract of Boufu of Production Example 3, Extract of Tribulus terrestris of Production Example 5, Extract of mixture of Tribulus terrestris, Tribulus terrestris, and Stem cell of Production Example 7) with a final concentration of 1250 μg / Addition was made to mL, 2500 μg / mL, 5000 μg / mL, and the culture was continued for 3 days.

3日間の培養後、細胞をPBS(−)にて3回洗浄した後、ラバーポリスマンにて集め、それぞれの細胞数をカウントした。 After culturing for 3 days, the cells were washed 3 times with PBS (−) and then collected with a rubber policeman, and the number of each cell was counted.

被験物質未添加時の総細胞数をコントロールとし、コントロールを100(%)とした場合の、被験物質添加時の細胞数の増減(%)を算出し、幹細胞増殖促進効果の評価を行った。
これらの試験結果を以下の表1に示す。
When the total number of cells when the test substance was not added was used as the control and the control was set to 100 (%), the increase / decrease (%) in the number of cells when the test substance was added was calculated, and the stem cell proliferation promoting effect was evaluated.
The results of these tests are shown in Table 1 below.

Figure 0006843425
Figure 0006843425

表1に示すように、ハマビシの抽出物、ボウフウの抽出物、アカヤジオウの抽出物、ならびにハマビシ、ボウフウ、及びアカヤジオウの混合物の抽出物には、いずれも顕著な幹細胞増殖促進効果が認められた。なお、上述のコントロールの値を100%とした場合、培養開始時のヒト成体幹細胞数は、25%であった。以上より、ハマビシ、ボウフウ、及びアカヤジオウ及びそれらの混合物の抽出物の極めて優れた幹細胞増殖促進効果を明らかにした。なお、本実験例で用いた幹細胞以外に、胚性の幹細胞(ES細胞)についても同様な試験を行ったところ、顕著な幹細胞増殖促進効果が認められた。 As shown in Table 1, the extract of Tribulus terrestris, the extract of Siler, the extract of Akayaziou, and the extract of the mixture of Tribulus terrestris, Siler, and Akayaziou all showed a remarkable effect of promoting stem cell proliferation. When the above-mentioned control value was set to 100%, the number of adult human stem cells at the start of culturing was 25%. From the above, it was clarified that the extracts of Tribulus terrestris, Siler, Rehmannia glutinosa and their mixtures have extremely excellent stem cell proliferation promoting effects. In addition to the stem cells used in this experimental example, a similar test was performed on embryonic stem cells (ES cells), and a remarkable effect of promoting stem cell proliferation was observed.

(実験例2)幹細胞に対する未分化状態維持効果の評価
Dulbecco’s Modified Eagle Medium培養液(Gibco社製)に、ウシ胎児血清(FBS、15%、Sigma社製)、ヌクレオシド液(100倍希釈、大日本製薬社製)、非必須アミノ酸液(100倍希釈、大日本製薬社製)、β2−メルカプトエタノール液(100倍希釈、大日本製薬社製)、L−グルタミン液(100倍希釈、大日本製薬社製)、ペニシリン(100unit/mL、Sigma社製)とストレプトマイシン(100μg/mL、Sigma社製)を加えて調製した培地を用いて、マウス胚性幹細胞(マウスES細胞:コスモバイオ社製)を、ゼラチン(Sigma社製)でコートした6cmディッシュに5x10個播種し、被験物質(製造例1のハマビシの抽出物、製造例3のボウフウの抽出物、製造例5のアカヤジオウの抽出物、製造例7のハマビシ、ボウフウ、及びアカヤジオウの混合物の抽出物)を最終濃度が1250μg/mLになるように培地に添加し、3日間培養を続けた。
(Experimental Example 2) Evaluation of undifferentiated state-maintaining effect on stem cells Fetal bovine serum (FBS, 15%, manufactured by Sigma) and nucleoside solution (diluted 100-fold, 100-fold diluted) were added to Dulvecco's Modified Eagle Medium culture medium (manufactured by Gibco). Dainippon Pharmaceutical Co., Ltd.), non-essential amino acid solution (100-fold dilution, Dainippon Pharmaceutical Co., Ltd.), β2-mercaptoethanol solution (100-fold dilution, Dainippon Pharmaceutical Co., Ltd.), L-glutamine solution (100-fold dilution, large) Mouse embryonic stem cells (mouse ES cells: manufactured by Cosmobio) using a medium prepared by adding penicillin (100 unit / mL, manufactured by Sigma) and streptomycin (100 μg / mL, manufactured by Sigma). ) Was seeded in 5x10 5 pieces on a 6 cm dish coated with gelatin (manufactured by Sigma), and the test substances (extract of Hamabishi of Production Example 1, extract of Fetal Bovine Serum of Production Example 3, and extract of Akayaziou of Production Example 5) were seeded. , An extract of a mixture of Hamabishi, Fetal bovine serum, and Akayajiou of Production Example 7) was added to the medium so as to have a final concentration of 1250 μg / mL, and the culture was continued for 3 days.

培養3日後に、細胞を回収し、PBS(−)にて2回洗浄し、Trizol Reagent(Invitrogen)によって細胞からRNAを抽出した。2−STEPリアルタイムPCRキット(Applied Biosystems)を用いて、抽出したRNAをcDNAに逆転写した後、ABI7300(Applied Biosystems)により、下記のプライマーセットを用いてリアルタイムPCR(95℃:15秒間、60℃:30秒間、40cycles)を実施し、Nanog(未分化マーカー: Cell Res. 2007 Jan; 17(1):42−9.Review. Nanog and transcriptional networks in embryonic stem cell pluripotency. Pan G, Thomson JA.)の遺伝子発現を確認した。その他の操作は定められた方法に従って実施した。 After 3 days of culturing, the cells were collected, washed twice with PBS (−), and RNA was extracted from the cells by Trizol Reagent (Invitrogen). After reverse transcribing the extracted RNA into cDNA using the 2-STEP real-time PCR kit (Applied Biosystems), real-time PCR (95 ° C: 15 seconds, 60 ° C.) using the following primer set using ABI7300 (Applied Biosystems). : 40 cycles) was carried out for 30 seconds, and Nanog (undifferentiated marker: Cell Res. 2007 Jan; 17 (1): 42-9. Gene expression was confirmed. Other operations were performed according to the prescribed method.

Nanog(未分化マーカー)用プライマーセット:
ATGCCTGCAGTTTTTCATCC(配列番号1)
GAGGCAGGTCTTCAGAGGAA(配列番号2)
Gapdh(内部標準)用のプライマーセット:
TGCACCACCAACTGCTTAGC(配列番号3)
TCTTCTGGGTGGCAGTGATG(配列番号4)
Primer set for Nanog (undifferentiated marker):
ATGCCTGCAGTTTTTCATCC (SEQ ID NO: 1)
GAGGCAGGGTCTTCAGAGGAA (SEQ ID NO: 2)
Primer set for Gapdh (internal standard):
TGCACCACCAACTGCTTAGC (SEQ ID NO: 3)
TCTTCTGGGTGTGCAGTGATG (SEQ ID NO: 4)

未分化状態維持効果は、培養開始時のマウスES細胞におけるNanog mRNAの発現量を内部標準であるGapdh mRNAの発現量に対する割合として算出したNanogの遺伝子相対発現量(Nanog遺伝子発現量/Gapdh遺伝子発現量)の値を100%未分化状態とし、これに対し、培養3日後のES細胞におけるNanogの遺伝子相対発現量の値を算出し、評価した。
これらの試験結果を以下の表2に示す。
The undifferentiated state maintenance effect is the relative expression level of Nanog (Nanog gene expression level / Gapdh gene expression) calculated as the ratio of the expression level of Nanog mRNA in mouse ES cells at the start of culture to the expression level of Gapdh mRNA, which is an internal standard. The value of (amount) was set to 100% undifferentiated state, and the value of the gene relative expression level of Nanog in ES cells 3 days after culturing was calculated and evaluated.
The results of these tests are shown in Table 2 below.

Figure 0006843425
Figure 0006843425

表2に示すように、ハマビシの抽出物、ボウフウの抽出物、アカヤジオウの抽出物、ならびにハマビシ、ボウフウ、及びアカヤジオウの混合物の抽出物には、いずれも顕著な幹細胞の未分化状態維持効果が認められた。なお、本実験例で用いた幹細胞以外に、体性の幹細胞についても同様な試験を行ったところ、顕著な幹細胞の未分化状態維持効果が認められた。 As shown in Table 2, the extract of Tribulus terrestris, the extract of Siler, the extract of Akayaziou, and the extract of the mixture of Tribulus terrestris, Siler, and Akayaziou all showed a remarkable effect of maintaining the undifferentiated state of stem cells. Was done. In addition to the stem cells used in this experimental example, a similar test was performed on somatic stem cells, and a remarkable effect of maintaining the undifferentiated state of the stem cells was observed.

以上の各実験例に示すように、ハマビシ、ボウフウ、及びアカヤジオウから選択される1種又は2種以上の植物の抽出物を幹細胞に適用することで、従来の技術に比べて、簡便且つ効率的に、未分化状態を維持させたまま幹細胞の増殖を促進させることが可能になった。 As shown in each of the above experimental examples, by applying an extract of one or more kinds of plants selected from Tribulus terrestris, Siler, and Rehmannia glutinosa to stem cells, it is simpler and more efficient than the conventional technique. In addition, it has become possible to promote the proliferation of stem cells while maintaining the undifferentiated state.

本発明の活用例として、再生医療や再生美容への応用が期待される。例えば、本発明を利用することで、再生医療や再生美容に用いる未分化状態の幹細胞を簡便に効率良く調製することが可能となる。さらに、幹細胞の移植後又は組織に存在する幹細胞に対して、本発明に係るハマビシ、ボウフウ、及びアカヤジオウから選択される1種又は2種以上の植物の抽出物を、直接的に注入するか又は経口投与、塗布、貼付等により適用することで、該幹細胞を、未分化状態を維持させたまま増殖させることが可能である。
すなわち、本発明は、再生医療や再生美容における、幹細胞の製造方法及び/又は幹細胞の未分化状態維持剤又は増殖促進剤としての利用が可能である。
As an example of utilization of the present invention, application to regenerative medicine and regenerative beauty is expected. For example, by using the present invention, it becomes possible to easily and efficiently prepare undifferentiated stem cells used for regenerative medicine and regenerative cosmetology. Furthermore, after transplantation of stem cells or to the stem cells existing in the tissue, one or more plant extracts selected from Tribulus terrestris, Siler, and Rehmannia glutinosa according to the present invention are directly injected or injected. By applying by oral administration, application, application, etc., the stem cells can be proliferated while maintaining an undifferentiated state.
That is, the present invention can be used as a method for producing stem cells and / or as an undifferentiated state-maintaining agent or a growth-promoting agent for stem cells in regenerative medicine and cosmetology.

Claims (5)

ハマビシ、ボウフウ、及びアカヤジオウの混合物熱水抽出物を有効成分として含有する幹細胞の未分化状態維持剤。 An undifferentiated state-maintaining agent for stem cells containing a hot water extract of a mixture of Tribulus terrestris, Siler, and Rehmannia glutinosa as an active ingredient. ハマビシ、ボウフウ、及びアカヤジオウの混合物熱水抽出物を有効成分として含有する幹細胞の増殖促進剤。 A stem cell growth promoter containing a hot water extract of a mixture of Tribulus terrestris, Siler, and Rehmannia glutinosa as an active ingredient. 幹細胞を、ハマビシ、ボウフウ、及びアカヤジオウの混合物熱水抽出物を含有する培地で培養する工程を含む、幹細胞の製造方法。 A method for producing stem cells, which comprises a step of culturing stem cells in a medium containing a hot water extract of a mixture of Tribulus terrestris, Siler, and Akayaziou. 幹細胞を、ハマビシ、ボウフウ、及びアカヤジオウの混合物熱水抽出物を含有する培地で培養する工程を含む、幹細胞の未分化状態維持方法。 A method for maintaining an undifferentiated state of stem cells, which comprises a step of culturing the stem cells in a medium containing a hot water extract of a mixture of Tribulus terrestris, Siler, and Akayajiou. 幹細胞を、ハマビシ、ボウフウ、及びアカヤジオウの混合物熱水抽出物を含有する培地で培養する工程を含む、幹細胞の増殖促進方法。 A method for promoting proliferation of stem cells, which comprises a step of culturing stem cells in a medium containing a hot water extract of a mixture of Tribulus terrestris, Siler, and Rehmannia glutinosa.
JP2016196171A 2016-10-04 2016-10-04 Stem cell undifferentiated state maintainer and growth promoter Active JP6843425B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2016196171A JP6843425B2 (en) 2016-10-04 2016-10-04 Stem cell undifferentiated state maintainer and growth promoter

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2016196171A JP6843425B2 (en) 2016-10-04 2016-10-04 Stem cell undifferentiated state maintainer and growth promoter

Publications (2)

Publication Number Publication Date
JP2018057301A JP2018057301A (en) 2018-04-12
JP6843425B2 true JP6843425B2 (en) 2021-03-17

Family

ID=61907460

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016196171A Active JP6843425B2 (en) 2016-10-04 2016-10-04 Stem cell undifferentiated state maintainer and growth promoter

Country Status (1)

Country Link
JP (1) JP6843425B2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108938687B (en) * 2018-09-03 2021-06-25 辽宁何氏医学院 Application of tribulus in preparation of medicine for preventing and treating retinal injury diseases
JP7178087B2 (en) * 2018-11-30 2022-11-25 日本メナード化粧品株式会社 Stem cell undifferentiated state maintenance agent and growth promoter
CA3154989A1 (en) * 2020-04-03 2021-10-07 Jong Hyun Nam Sexual function improving composition comprising extracts of orostachys japonicus and vigna vexillata

Also Published As

Publication number Publication date
JP2018057301A (en) 2018-04-12

Similar Documents

Publication Publication Date Title
JP6843425B2 (en) Stem cell undifferentiated state maintainer and growth promoter
JP6535505B2 (en) An agent for maintaining undifferentiated state of stem cells and an agent for promoting proliferation using the extract of Mannengtake mushroom
JP6583679B2 (en) Stem cell undifferentiated state maintenance agent and growth promoter using yeast extract
JP5819209B2 (en) Differentiation promoter from stem cells to brown adipocytes
JP6411778B2 (en) Stem cell undifferentiated state maintenance agent and growth promoter
JP6571494B2 (en) Stem cell undifferentiated state maintenance agent and growth promoter using Ainu Wakame
JP6468895B2 (en) Stem cell undifferentiated state maintenance agent and growth promoter
JP6649050B2 (en) Stem cell undifferentiated state maintenance agent and growth promoter
JP6615589B2 (en) Stem cell undifferentiated state maintenance agent and growth promoter
JP6587899B2 (en) Stem cell undifferentiated state maintenance agent and growth promoter
JP6697252B2 (en) Stem cell undifferentiated state maintenance agent and growth promoter
CN107075474B (en) Agent for maintaining undifferentiated state of stem cells and agent for promoting proliferation of stem cells
JP6844829B2 (en) Stem cell undifferentiated state maintainer and growth promoter
JP6877014B2 (en) Stem cell undifferentiated state maintainer and growth promoter
JP6763604B2 (en) Stem cell undifferentiated state maintainer and growth promoter
JP7178087B2 (en) Stem cell undifferentiated state maintenance agent and growth promoter
JP2014065672A (en) Promoter for differentiation of stem cell into brown fat cell
JP6159183B2 (en) Stem cell-derived growth factor production promoter
JP7202610B2 (en) Stem cell undifferentiated state maintenance agent and growth promoter
JP7214191B2 (en) Stem cell undifferentiated state maintenance agent and growth promoter
JP6529791B2 (en) Agent for maintaining undifferentiated state of stem cells and growth promoter
JP7287653B2 (en) Proliferation promoter for stem cells
JP6840376B2 (en) Stem cell undifferentiated state maintainer and growth promoter
JP7454215B2 (en) Stem cell proliferation promoter
JP7319611B2 (en) Proliferation promoter for stem cells

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190819

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200918

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210126

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210216

R150 Certificate of patent or registration of utility model

Ref document number: 6843425

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250